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Abstract
Mammals have two parallel vascular systems, the blood and the lymphatic vascular 
system. The blood vascular system is a closed system that transports oxygen and 
nutrients to tissues and metabolic wastes from the tissues to excretory organs. The 
lymphatic system is unidirectional and consists of blind-ended lymphatic capillaries, 
which collect excess fluid from the interstitial space and transport it first into larger 
caliber collecting lymphatic ducts and finally through the lymph nodes back into the 
bloodstream via a connection in the subclavian vein. Thus, the lymphatic system 
helps maintain fluid homeostasis. Like veins, lymphatic collecting ducts contain 
intraluminal valves that ensure unidirectional flow.
Notch signaling is an evolutionary conserved signaling pathway that mediates cell 
fate decisions and regulates cellular functions through its modulation of downstream 
targets. Using transgenic mouse models, we studied the role of Notch in embryonic 
lymphatic development and postnatal blood vascular development. 
Lymphatic development begins at embryonic day 9.75 when a subset of 
endothelial cells in the cardinal vein start expressing Prox1 and other lymphatic 
markers and become committed to the lymphatic lineage. We show that loss of 
Notch during the initiation phase leads to an increase in Prox1+ lymphatic progenitor 
cells emerging from the cardinal vein and lymphatic overgrowth. Thus, Notch is 
required in the cardinal vein to limit the number of endothelial cells adopting the 
lymphatic endothelial fate. After lymphatic endothelial specification, lymphatic valve 
formation begins at embryonic day 15.5, as subsets of lymphatic endothelial cells in 
the lymphatic duct walls adopt a lymphatic valve fate and separate from the ductal 
wall cells. Valve-forming lymphatic endothelial cells express high levels of Prox1 
(Prox1high) while the ductal wall lymphatic endothelial cells express lower amounts 
(Prox1low). Valve-forming lymphatic endothelial cells also express integrin-α9, 
fibronectin-EIIIA and Connexin37, all of which are necessary for proper valve 
morphogenesis. We show that loss of Notch signaling in lymphatic endothelial cells at 
the time of valve initiation results in a disruption of the Prox1high/Prox1low expression 
pattern, a decrease in the number of valves, and abnormal valve morphology. Loss 
of Notch also resulted in reduced integrin-α9 and fibronectin-EIIIA expression in 
valve-forming lymphatic endothelial cells. Thus, Notch signaling is required for 
proper lymphatic valve development and induction of key lymphatic valve proteins 
during valve morphogenesis. 
Blood endothelial cells interact with contractile smooth muscle cells and non-
contractile pericytes, which are collectively called mural cells. Endothelial cell-mural 
cell interactions provide mechanical support to vessels as well as regulate many 
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vessel functions that are crucial for vascular integrity such as permeability, sprouting 
and quiescence. Notch1 is expressed in both endothelial cells and mural cells while 
Notch3 is restricted to vascular mural cells cells. Using a genetic approach, we show 
that global Notch1 heterozygocity combined with global Notch3 deficiency results 
in impaired vascular smooth muscle cell recruitment in the mouse retina leading 
to abnormal vascular development. We also demonstrate that biological inhibition 
of Notch signaling using soluble Notch1 decoys results in defective vascular smooth 
muscle coverage in the mouse retina. Our data show that both Notch1 and Notch3 
are required for proper vascular smooth muscle cell function during vascular 
development and thus report a novel role for Notch1 in mural cells.
12
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1. BLOOD VASCULATURE
STRUCTURE AND EMBRYONIC DEVELOPMENT
The blood vascular system consists of the heart, arteries, veins and capillaries 
connecting the arterial and venous circulation. The main function of the vascular 
system is to deliver oxygenated blood, nutrients and hormones to tissues and remove 
carbon dioxide and other metabolic waste products from the tissues. The heart 
pumps the blood through the arteries into the capillary network where the exchange 
of gases and nutrient absorption occurs. The capillary network connects to the 
venous side, which returns the blood back into the heart. The vessels of arteries 
and veins consist of three distinct layers. The innermost, thinnest layer (tunica 
intima) consists of a single layer of endothelial cells (ECs), which are adjoined by 
tight and adherens junctions and surrounded by basement membrane. Endothelial 
cells regulate multiple blood vessel functions including blood flow and vessel 
permeability, as well as respond to growth factors that promote formation of new 
blood vessels. The middle layer (tunica media) of blood vessels consists of connective 
tissue, elastic fibers and vascular smooth muscle cells (VSMCs). It is the thickest 
layer in arteries, as the higher arterial blood pressure requires a thicker layer of 
VSMCs than veins to maintain vessel integrity. The outermost layer (tunica externa) 
is the thickest layer in veins and consists entirely of connective tissue. Larger caliber 
veins contain intraluminal valves that prevent the backflow of blood and help keep 
it flowing toward the heart. Blood capillaries consist of one layer of endothelial cells 
surrounded by basement membrane (BM), which allows the exchange of substances 
between the capillaries and tissues. Blood capillaries are supported by pericytes, 
which share a basement membrane with the endothelial cells and help regulate 
vascular functions such as permeability, sprouting and quiescence (reviewed in 
(Coultas et al., 2005)).
The cardiovascular system is the first functional system in a developing vertebrate 
embryo. In mice, the heart starts beating around embryonic day (E) 7.0. Embryonic 
blood vessels initially develop separate from the heart and connect to it later on. The 
de novo formation of blood vessels occurs through a process called vasculogenesis 
(reviewed in (Risau and Flamme, 1995)). At E7.0 common blood and endothelial 
cell progenitor cells called hemangioblasts aggregate and form blood islands in 
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the yolk sac. Subsequently, the inner hemangioblasts of the blood island become 
non-adherent hematopoietic progenitor cells, haemocytoblasts, while the outer 
hemangioblasts become the adherent endothelial progenitor cells, angioblasts. 
There is, however, some debate over the process and whether blood and ECs actually 
have a common progenitor (Eichmann et al., 2002; Fleury et al., 2015). After the 
initial phase of vasculogenesis, angioblasts divide and differentiate into ECs, which 
subsequently form a primary blood vascular plexus (reviewed in (Coultas et al., 
2005)). The primary plexus is then remodeled via angiogenesis which involves 
sprouting as well as pruning of unnecessary connections into a mature vascular 
network (reviewed in (Potente et al., 2011)). Physiological vasculogenesis occurs 
primarily during embryonic development. Angiogenesis is active both embryonically 
and postnatally, for instance during wound healing and in female reproductive 
tissue. Both vasculogenesis and angiogenesis can occur in adult organisms in 
pathological settings, e.g. in tumors.
SPROUTING ANGIOGENESIS
During angiogenesis, pro-angiogenic growth factors, e.g. vascular endothelial growth 
factor (VEGF) stimulate pre-existing blood vessels to sprout and form new vessels 
(Gerhardt et al., 2003; Potente et al., 2011). One of the main triggers of angiogenesis 
is tissue hypoxia. In the mouse retina, hypoxic cells release pro-angiogenic growth 
factors, most importantly VEGF, that spread into the surrounding tissue forming 
a growth factor gradient (Ruhrberg et al., 2002). ECs of existing blood vessels 
express receptors for these growth factors, most commonly the members of the 
vascular endothelial growth factor receptor (VEGFR) family (Gerhardt et al., 2003). 
Growth factor-receptor interaction stimulates proliferation and migration of ECs 
toward higher concentration of a pro-angiogenic stimulus (VEGF) thus leading 
the angiogenic sprout to the hypoxic tissue (Gerhardt et al., 2003; Ruhrberg et 
al., 2002). Subsequently the newly formed vessels become lumenized, secrete a 
basement membrane, connect to each other through anastomosis, recruit mural 
cells and become a mature, quiescent vascular network.
During angiogenesis the ECs of the growing sprout are specified into tip cells 
and stalk cells (Gerhardt et al., 2003). Tip cells extend filopodia and express growth 
factor receptors that allow them to sense pro-angiogenic cues in the surrounding 
tissues and guide the nascent sprout toward the source of the growth factor gradient 
(Gerhardt et al., 2003). Stalk cells are situated behind the tip cells in the angiogenic 
sprouts and they are less responsive to the pro-angiogenic guidance cues (Gerhardt 
et al., 2003). They are proliferative and therefore responsible for the actual growth of 
the sprout (Gerhardt et al., 2003). In order to ensure the formation of an appropriate 
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amount of angiogenic sprouts, the tip cells inhibit the surrounding cells from 
adopting the tip cell fate through lateral inhibition, via the Notch pathway, once 
they have established their position (Hellstrom et al., 2007; Lobov et al., 2007; 
Suchting et al., 2007). However, it is thought that the tip/stalk cell identity is a 
very transient and plastic state and that there is constant competition between the 
ECs in a growing sprout for the tip cell position.
The blood vasculature of mature tissues is usually quiescent. Physiological 
sprouting angiogenesis in adult organisms is mainly observed during the female 
reproductive cycle, during tissue regeneration and wound healing making it 
challenging to study physiological angiogenesis outside the embryonic setting. 
However, the murine retina is avascular at birth and becomes vascularized in a highly 
consistent manner during the first three postnatal weeks, making it an excellent 
model for studying the different aspects of sprouting angiogenesis, including mural 
cell recruitment and coverage (Figure 1) (Gerhardt et al., 2003). During the first 
postnatal week, blood vessels grow from the optic nerve towards the retinal periphery 
forming the superficial vascular plexus. Subsequently during the next two weeks, the 
vessels dive perpendicularly and form the deep and intermediate vascular networks 
(Gerhardt et al., 2003). Observing the retinal vasculature at P5 allows the study 
of active sprouting angiogenesis, including determining the number of tip cells, 
branch points as well as mural cell recruitment. Analysis at P8 enables the study 
of aspects associated with a more mature network, such as arterio-venous and 
capillary differentiation, vascular density and mural cell coverage. At later time-
points, P12-P21 the functionality of retinal network can be assessed.
Figure 1. The postnatal vascularization of the 
mouse retina provides an excellent model 
for the study of sprouting angiogenesis. 
Flat-mounted retinas allow visualization and 
study of different aspects of angiogenesis. 
During the first postnatal week blood vessels 
grow from the optic nerve towards the retinal 
periphery. Upon reaching the edges, the vessels 
dive perpendicularly and form the deep and 
intermediate retinal vascular networks. Tip cells 
can be seen at the leading tips of the growing 
vessels (white arrows). Adapted from Gerhardt 
et al. 2003. VEGF guides angiogenic sprouting 
utilizing endothelial tip cell filopodia. Journal 
of Cell Biology; 161 (6): 1163-77. © Gerhardt 
et al. Journal of Cell Biology. 161:1163-1177. 
doi:10.1083/jcb.200302047
Figure 1. The postnatal vascularization of the mouse retina
provides an excellent model for the study of sprouting
angiogenesis. Flat-mounted retinas allow visualization and study of
different aspects of angiogenesis. During the first postnatal week
blood vessels grow from the optic nerve towards the retinal
periphery. Upon reaching the edges, the vessels dive perpendicularly
and form the deep and intermediate retinal vascular networks. Tip
cells can be seen at the leading tips of the growing vessels (white
arrows). Adapted from Gerhardt et al. 2003. VEGF guides
angiogenic sprouting utilizing endothelial tip cell filopodia. Journal
of Cell Biology; 161 (6): 1163-77. © Gerhardt et al. Journal of Cell
Biology. 161:1163-1177. doi:10.1083/jcb.200302047
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MURAL CELLS
Mural cells have typically been divided into vascular smooth muscle cells (VSMCs) and 
pericytes. However, recent discoveries suggest that there is a continuum of different mural 
cell phenotypes rather than only two clearly distinguishable cell types (reviewed in (Armulik 
et al., 2011)). In this continuum pericytes represent a plastic, relatively undifferentiated 
mural cell population while vascular smooth muscle cells would be a more terminally 
differentiated and mature cell type. Pericytes have proven challenging to define conclusively 
by cell surface markers, many of which are common with fibroblasts and mesenchymal stem 
cells. In addition, pericytes display significant phenotypic heterogeneity and embryonically 
originate from multiple tissue types (reviewed in (Armulik et al., 2011; Gaengel et al., 2009)). 
In blood vasculature, contractile VSMCs are found around arteries and arterioles as well as 
to lesser extent around veins and venules. They wrap themselves around the blood vessels 
providing mechanical support and help regulate vessel tone and diameter but are separated 
from the endothelium by a basement membrane. In lymphatic vasculature, VSMCs are 
recruited to larger caliber collecting lymphatic ducts where they facilitate the movement 
of lymph in the collecting ducts. Both VSMCs and pericytes express PDBFR-β, but only 
mature VSMCs express contractile proteins like α smooth muscle actin (αSMA) and myosin 
heavy chain, which are used to identify the cell type (Figure 2). Like pericytes, VSMCs 
have diverse origins (reviewed in (Armulik et al., 2011)). Pericytes are defined as mural cells 
lining smaller caliber vessels and sharing basement membrane (BM) with the endothelial 
cells. They have an intimate association with the endothelial cells; the two cell types are 
directly connected through cellular processes they participate in and through sharing of the 
BM in which pericytes are embedded. Pericytes do not express contractile proteins and 
are typically identified as cells expressing NG2, PDBFR-β and desmin. It should be noted, 
however, that some VSMCs also express NG2, which is why several markers should be 
used to conclusively distinguish the two mural cell types.
Mural cells are crucial for the maintenance of vascular integrity. Pericytes 
regulate several aspects of EC biology including proliferation, EC-EC junctions, 
permeability and sprouting (Hellstrom et al., 2001; Stratman et al., 2009). VSMCs 
support larger vessels and are especially crucial for arteries, which due to high blood 
pressure require mechanical support. By contracting they also provide a pumping 
function to help move blood along in the vessels. During sprouting angiogenesis, 
endothelial cells recruit pericytes to the nascent sprouts and VSMCs to arteries and 
veins. The subsequent pericyte association with the endothelium induces basement 
membrane deposition and inhibits sprouting thus promoting vessel maturation and 
quiescence (reviewed in (Armulik et al., 2011; Stratman et al., 2009)). The central 
nervous system (CNS) is considered the most pericyte rich tissue and pericytes have 
been shown to be crucial for establishment and maintenance of the blood-brain-
barrier (BBB) (Armulik et al., 2010; Daneman et al., 2010). Cerebral VSMCs are 
required to maintain vascular integrity in the brain. Indeed, gradual loss of brain 
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VSMCs coverage seen in the lethal human syndrome CADASIL (cerebral autosomal-
dominant arteriopathy with subcortical infarcts and leukoencephalopathy) causes 
vessel leakage and strokes (Joutel et al., 1996; Ruchoux et al., 1995).
2. LYMPHATIC VASCULATURE
STRUCTURE OF THE LYMPHATIC VASCULATURE AND  
LYMPHATIC ENDOTHELIAL PHENOTYPES
Due to high blood pressure on the arterial side of the blood capillary bed fluid 
and molecules continuously leak into the interstitial space. One of the functions 
of the lymphatic system is to maintain tissue homeostasis by collecting this excess 
fluid and macromolecules and returning them into the bloodstream. In addition, 
the lacteal lymphatic capillaries in the villi of small intestine absorb dietary fats 
and vitamins from the intestines. Finally, the lymphatic vasculature is essential for 
immune surveillance as it transports antigen-presenting cells into lymph nodes and 
provides a route for other immune cells to be transported throughout the body. 
The lymphatic vasculature consists of lymphatic capillaries, intermediate size 
pre-collecting ducts, larger collecting ducts and lymph nodes, which they connect 
to (Figure 3). Unlike the blood vascular system, there is no central pump in 
the lymphatic vasculature and flow is maintained through compression by 
surrounding skeletal muscles and contractile VSMCs in larger caliber lymphatic 
Figure 2. Localization of vascular smooth muscle cells and pericytes
in the mouse retina. αSMA /NG2 positive VSMCs are only seen lining
arterioles while αSMA negative/NG2 positive pericytes are found
associating with both arterioles and smaller caliber vessels in a P5
mouse retina. White arrows mark double positive VSMCs and red
arrowheads NG2 single positive pericytes. Blood vessels visualized by
isolectin B4 (gr en). Scalebars 50µm.
iB4 αSMA NG2 αSMA NG2
Figure 2. Localizati n of vascular smooth muscle cells and pericytes in the mouse retina. αSMA /NG2 
positive VSMCs are only seen lining arterioles while αSMA negative/NG2 positive pericytes are found 
associating with both arterioles and smaller caliber vessels in a P5 mouse retina. White arrows mark double 
positive VSMCs and red arrowheads NG2 single positive pericytes. Blood vessels visualized by isolectin 
B4 (green). Scalebars 50µm.
17
vessels (Figure 3). Different parts of the lymphatic system have distinct functions, 
which are reflected by their specialized structures. Lymphatic capillaries which are 
responsible for fluid uptake, consist of a single layer of “oak-leaf” shaped lymphatic 
endothelial cells (LECs) that are connected by discontinuous button-like junctions. 
Junction proteins such as VE-cadherin are clearly localized in the junctions and 
absent from areas between the junctions (reviewed in (Schulte-Merker et al., 
2011)). Lymph, consisting of interstitial fluid, lymphocytes and proteins, enters into 
capillary lumens through these gaps between the junctions as the interstitial pressure 
increases due to fluid accumulation. To further aid the passive entry of lymph, 
lymphatic capillaries are surrounded by a discontinuous basement membrane 
(BM) and lack mural cell coverage. LECs in lymphatic capillaries are attached to 
the surrounding extracellular matrix (ECM) through anchoring filaments which 
dilate the vessels opening the junctions during increased tissue pressure (Figure 
3) (reviewed in (Schulte-Merker et al., 2011)). Lymph is transported from the 
lymphatic capillaries into pre-collecting ducts and finally to larger caliber collecting 
lymphatic ducts. Pre-collecting ducts display some lymphatic capillary-like and 
some collecting duct-like features. LECs in pre-collecting ducts exhibit the same 
oak-leaf shape as LECs in lymphatic capillaries but also contain intraluminal valves 
and sparse VSMC coverage, features usually associated with large collecting ducts 
(reviewed in (Schulte-Merker et al., 2011)). Unlike capillary LECs, collecting duct 
LECs are elongated and connected by tight, continuous zipper-like junctions with 
uninterrupted VE-cadherin localization along the junction. Furthermore, collecting 
ducts are surrounded by a continuous basement membrane and VSMCs (reviewed in 
(Schulte-Merker et al., 2011)). Thus, the structure of collecting ducts prevents leakage 
during lymph transport (continuous junctions and BM) and facilitates flow (VSMCs). 
Furthermore, collecting ducts contain intraluminal valves that ensure unidirectional 
flow of the lymph. Valves open in response to lymph pressure upstream of the valve 
allowing the lymph to flow. Once the lymph has passed through the valve it creates 
reverse flow, which pushes the valve leaflets towards each other closing the valve 
and thus preventing backflow. From collecting ducts lymph is transported through 
the lymph nodes into the thoracic duct or the right lymphatic duct and finally 
back into the blood vascular system through the left and right internal jugular and 
subclavian veins (Figure 3).
During embryonic development, LECs are derived from venous endothelial 
cells and adopt a lymphatic fate that consists of unique features different from 
BEC; that is, they express a distinct set of markers (Srinivasan et al., 2007). 
However, lymphatic marker expression varies significantly between different 
LEC populations depending on their developmental stage and location within 
the lymphatic vasculature. Transcription factor Prox1, often referred to as the 
lymphatic master regulator, is crucial for the initial lymphatic specification as well 
18
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as maintenance of the lymphatic endothelial phenotype (Oliver et al., 1993; Oliver 
and Srinivasan, 2010; Wigle and Oliver, 1999). Indeed, Prox1 is expressed by all 
LECs throughout development and adulthood (Johnson et al., 2008). Hyaluronan 
receptor, LYVE1, is expressed by LECs precursors during embryonic development 
and transiently in collecting ducts before being dramatically downregulated in duct 
LECs during lymphatic maturation between E17.5-P9 (Norrmen et al., 2009; Oliver, 
2004). Strong expression of LYVE1 is only maintained in lymphatic capillaries 
(Makinen et al., 2005). Similarly, VEGFR-3 expression is strong in all LECs 
during development, maintained in capillaries while down-regulated in collecting 
ducts during maturation (Norrmen et al., 2009). VEGFR-3 co-receptor Nrp2 is 
strongly expressed by a subset of LECs during development with some expression 
maintained in mature collecting ducts. VEGFR-2 is expressed in collecting ducts 
during development and strong expression is also seen in developing and mature 
lymphatic valves (Yuan et al., 2002). Valve-LECs are a distinct population of LECs 
that separate from lymphatic duct wall LECs during valve morphogenesis. Valve-
LECs express high levels of Prox1, Foxc2, VEGFR-2, VEGFR-3 (also known as Flt4) 
Figure 3. The lymphatic system. Lymphatic capillaries collect excess fluid
from tissues and via collecting lymphatic vessels transport it back into the
bloodstream. Lymphatic capillaries have a discontinuous basement membrane
and no smooth muscle cell coverage to facilitate fluid absorption. Collecting
vessels are lined by smooth muscle cells that provide mechanical support and
move lymph forward. Intraluminal valves prevent backflow of fluid. Adapted
from Maby-El Hajjami and Petrova. Developmental and pathological
lymphangiogenesis: from models to human diseases. Histochemistry and Cell
Biology .December 2008. 130(6): 1063-1078. © The Author(s) 2008. With
permission of Springer Science+Business Media.
Lymphatic capillaries
Collecting lymphatic vessel
Basement membrane
Pre-collecting 
lymphatic vessel
Valve
Smooth muscle cells
Anchoring filaments
Extracellular matrix
Subclavian vein
Lymph node
Efferent 
vessel
Afferent vessel
Figure 3. The lymphatic system. Lymphatic capillaries collect excess fluid from tissues and via collecting 
lymphatic vessels transport it ba k into the bloodstream. Lymphatic capillaries have a discontin ous 
basement membrane and no smooth muscle cell coverage to facilitate fluid absorption. Collecting vessels are 
lined by smooth muscle cells that provide mechanical support and move lymph forward. Intraluminal valves 
prevent backflow of fluid. Adapted from Maby-El Hajjami and Petrova. Developmental and pathological 
lymphangiogenesis: from models to human diseases. Histochemistry and Cell Biology .December 2008. 
130(6): 1063-1078. © The Author(s) 2008. With permi sion of Springer Scien e+Business Media.
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and gap-junction protein 37 (Cx37), both in forming and mature valves (Kanady 
et al., 2011; Norrmen et al., 2009; Petrova et al., 2004; Wirzenius et al., 2007). In 
addition, valve-LECs express integrin-α9 and fibronectin splice variant-EIIIA (FN-
EIIIA), which are not seen in other LECs and can thus be used as valve-specific 
markers (Bazigou et al., 2009).
Mesenteric lymphatic vessels can be easily dissected out together with the 
intestines and clearly visualized as the mesentery is transparent (Figure 4). 
Therefore, the mesentery is an excellent tissue to utilize for lymphatic studies and 
widely used in the field. Whole-mount preparations of the mesentery allow the 
morphological study of mesenteric collecting ducts as well as the lymphatic valves 
they contain. Mesenteric collecting ducts run side by side with mesenteric arteries 
and veins, which can be used as controls to ensure that the observed effects are 
lymphatic specific. 
Figure 4. The mesentery can be utilized to study collecting lymphatic vessel and lymphatic valve 
morphology. Small intestine of a P5 mouse imaged under a light microscope. Fluorescently stained images 
represent examples of the structures seen in boxed areas showing mesenteric collecting lymphatic ducts 
containing lymphatic valves and mesenteric arteries and veins running side by side with the lymphatic 
vessels. White arrows mark PROX1/INTEGRIN-α9 double positive lymphatic valves. A, artery; L, lymphatic 
collecting duct; V, vein.
EMBRYONIC DEVELOPMENT
The lymphatic system is derived from the embryonic veins. The venous origin of 
lymphatic structures has been confirmed both in mice and zebrafish suggesting 
the process is evolutionary conserved (Srinivasan et al., 2007). In mice, lymphatic 
development begins around midgestation when a subset of ECs in the cardinal veins 
(CV) begins expressing lymphatic markers and become committed to the lymphatic 
lineage (Figure 5). Subsequently, current models propose that lymphatic vascular 
morphogenesis proceeds through two distinct mechanisms: “ballooning” of the 
LEC clusters out of the CVs and direct delamination of LECs from the CV. The 
ballooning LEC clusters form primitive lymph sacs while the primary lymphatic 
vessel network is formed through a combination of direct migration of cells from 
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Figure 4. The mesentery can be utilized to study collecting lymphatic vessel and lymphatic valve morphology. Small
intestine of a P5 mouse imaged under a light microscope. Fluorescently stained images represent examples of the structures
seen in b xed areas showing m senteric collecting lymphatic ducts containing lymphatic valves and mesenteric arteries and
veins running side by side with the lymphatic vessels. White arrows mark PROX1/INTEGRIN-α9 double positive lymphatic
valves. A, artery; L, lymphatic collecting duct; V, vein.
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the CV and sprouting from the lymph sacs (François et al., 2011). Similar to blood 
vascular development, the primary lymphatic plexus is remodeled into a mature 
lymphatic vasculature with capillaries and larger lymphatic collecting ducts. During 
maturation, valves are formed in the collecting ducts and they acquire a basement 
membrane and VSMCs while capillaries become highly permeable structures 
specialized in fluid absorption. In mice, lymphatic maturation continues during 
the first two postnatal weeks when the superficial capillary networks are formed. 
Although the lymphatic vasculature is the less studied of the two vascular systems, 
significant advances have been made in understanding lymphatic development and 
regulators during the past decade.
Figure 5. Lymphatic specification. Lymphatic specification occurs on the dorso-lateral side of the cardinal 
vein where two populations of LEC progenitors can be seen. Prox1high/LYVE-1high/Nrp2low LEC progenitors 
form clusters which subsequently bud off to form the lymph sacs. At the same time, individual Prox1high/
LYVE-1low/Nrp2high LEC progenitors migrate out of the CV. The primary lymphatic plexus is formed between 
E11.5-E14.5 by a combination of sprouting from the lymph sacs and the individual progenitors delaminating 
from the CV. The primary plexus is then remodeled into a mature lymphatic network between E14.5-P14 
through sprouting and pruning. During maturation, lymphatic capillaries and collecting lymphatic ducts 
acquire their specialized features and typical marker expression. Based on Francois et al. 2012.  Segmental 
territories along the cardinal veins generate lymph sacs via a ballooning mechanism during embryonic 
lymphangiogenesis in mice. Developmental Biology; 364 (2): 89-98.
Early lymphatic specification: Sox18, Coup-TFII, Prox1 and LYVE1
In mice, LEC specification occurs around embryonic day 9.75 in the cardinal vein 
when a subset of venous endothelial cells expressing transcription factor Prox1 
and hyaluronan receptor LYVE1 adopt the lymphatic phenotype (Srinivasan et al., 
Figure 5. Lymphatic specification. Lymphatic specification occurs on the dorso-lateral side of the cardinal vein where two
populations of LEC progenitors can be seen. Prox1high/LYVE-1high/Nrp2low LEC progenitors form clusters which subsequently
bud off to for the lymph sa s. At he same time, individual Prox1high/LYVE-1low/Nrp2high LEC progenitors migrate out of the
CV. The primary lymphatic plexus is formed between E11.5-E14.5 by a combination of sprouting from the lymph sacs and the
individual progenitors delaminating from the CV. The primary plexus is then remodeled into a mature lymphatic network
between E14.5-P14 through sprouting and pruning. During maturation, lymphatic capillaries and collecting lymphatic ducts
acquire their specialized features and typical marker expression. Based on Francois et al. 2012. Segmental territories along the
cardinal veins generate lymph sacs via a ballooning echanism during embryonic lymphangiogenesis in mice. D velopmental
Biology; 364 (2): 89-98.
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2007; Wigle et al., 2002; Wigle and Oliver, 1999). Prox1 is absolutely required for 
lymphatic development as demonstrated by loss of LEC specification and lack of 
all lymphatic structures in Prox1-/- mice (Wigle and Oliver, 1999). Prox1 expression 
maintains the lymphatic phenotype and is thus necessary in LECs beyond embryonic 
development: loss of Prox1 after completion of lymphatic development results in 
partial loss of LEC marker expression and misexpression of BEC markers by LECs 
and edema (Johnson et al., 2008). In vitro studies support a Prox1 function as 
lymphatic master regulator, where ectopic Prox1 expression causes upregulation of 
lymphatic regulators, such as SLC (Ccl21), Nrp2, podoplanin and integrin-α9 and 
downregulation of BEC genes, such as CD34, Nrp1 and endoglin. In embryonic 
development, Prox1 expression is induced by transcription factors Sox18 and Coup-
TFII (Francois et al., 2008; Lee et al., 2009; Srinivasan et al., 2010). Sox18-/-embryos 
die by E14.5 and show a complete lack of LECs while Sox18+/- mice display mild 
edema and defective lymphatic vessel patterning demonstrating that Sox18 is crucial 
for normal lymphatic development (Francois et al., 2008). Coup-TFII is required 
for neural and cardiovascular development and Coup-TFII null mice display edema 
and hemorrhaging and die around E10.0 due to heart and vascular remodeling 
defects (Pereira et al., 1999). Endothelial specific deletion of Coup-TFII results 
in a dramatic reduction of Prox1+ LECs in the CV revealing its role in promoting 
lymphatic development. Sox18 expression is seen in the anterior cardinal vein 
prior to Prox1 expression and in vitro studies show that Sox18 binds directly to 
the Prox1 promoter (Francois et al., 2008). Coup-TFII is co-expressed with Prox1 
in LECs in the CV and around the CV at E11.5, and in lymph sacs and lymphatic 
vessels later during development and postnatally (Lee et al., 2009; Srinivasan et 
al., 2010). As Coup-TFII binds to an evolutionary conserved binding site of Prox1 
regulatory elements, it is thought to directly induce Prox1 expression (Srinivasan et 
al., 2010). After E13.5 Prox1 expression no longer requires Sox18 or Coup-TFII and 
is maintained through mechanisms that have not yet been elucidated (Srinivasan 
et al., 2010). Consistent with this, Sox18 expression is no longer detected in LECs 
after E14.5 indicating it is only transiently required for LEC specification, perhaps 
only to induce Prox1 expression during the initial steps of lymphatic development. 
However, Coup-TFII still cooperates with Prox1 to drive the expression of some LEC 
genes, such as Vegfr3 and Nrp2 (Lin et al., 2010). Prox1 and Coup-TFII have been 
shown to jointly regulate the formation of lymphovenous valves (Srinivasan and 
Oliver, 2011). Therefore, Sox18/Coup-TFII/Prox1 forms the crucial signaling axis 
that initiates LEC specification. While Sox18 and Coup-TFII induce Prox1 in LEC 
progenitors, it remains unresolved what induces Sox18 and Coup-TFII expression 
in endothelial cells in the CV.
LYVE1 expression is detected in the CV as early as E8.5 and its expression together 
with Prox1 is traditionally said to mark the initiation of lymphatic development. 
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However, the exact role of LYVE1 in the CV during early lymphatic specification is 
not clear. LYVE1 deficient mice are viable and only display mild lymphatic vessel 
dilation in organs with high cell turnover (Gale et al., 2007). Although the exact 
function of LYVE1 in the CV is unknown, LYVE1 expression seems to faithfully 
mark the newly specified LECs and is therefore commonly used to identify LECs 
during embryonic development. 
Lymphatic sprouting: VEGF-C/VEGFR-3 signaling and neuropilin 2
An original model of lymphatic development posits that Prox1+/LYVE1+/VEGFR-3+ 
LEC progenitors are situated on the dorso-lateral side of the CV and migrate out of 
the CV to form the lymphatic structures. More specifically, lymph sac formation is 
thought to occur as the LEC progenitors migrate out of the CV towards the embryo 
periphery guided by VEGF-C. These LECs cluster form primitive lymph sacs while 
lymphatic vessels are thought to form by LEC proliferation and sprouting from 
the lymph sacs. Recently it has been shown that Prox1 and LYVE1 expression are 
not uniformly distributed along the length of the CV. Instead, at E11.5, there are 
condensations of LEC progenitors expressing high levels of Prox1 and LYVE1 and 
low levels of Nrp2 that form so called “pre-lymphatic clusters” (PLC) along the 
antero-posterior axis of the CV (Figure 5) (François et al., 2011). Francois et al. 
showed that LEC progenitors in these PLCs give rise to primitive lymph sacs by 
“ballooning” out of the CV as a cell cluster. The PLCs stay connected to the CV until 
E12.5 when they pinch off as the lymphatic system separates from the blood vascular 
system. The nascent lymph sacs envelop blood cells as they pinch off, which explains 
why the presence of blood cells has been noted in several studies. The Francois 
group also showed that there is a separate LEC precursor population in the CV that 
expresses lower levels of Prox1 and LYVE1 than the LEC progenitors in the PLCs but 
higher levels of Nrp2. These LEC progenitors delaminate directly out of the CV and 
migrate towards the embryo periphery and, together with the LECs sprouting out 
of the primitive lymph sacs, form the lymphatic vessels. In support of this model, 
Nrp2 is not required for the formation of lymph sacs but is necessary for lymphatic 
capillary formation, thus defining distinct mechanisms for each process (Yuan et 
al., 2002). Interestingly, recent data suggest that a large part of superficial dermal 
lymphatic capillaries in murine embryos is formed by cells of non-venous origin 
and independently of venous-derived lymphatic capillaries (Martinez-Corral et al., 
2015). Martinez-Corral et al. showed that these non-venous progenitor cells start 
clustering at E12.5 in the embryo periphery and form lymphatic capillaries that only 
later, at E17.5, connect to the venous-derived lymphatic capillaries (Martinez-Corral 
et al., 2015). Although these non-venous progenitor cells remain to be identified, 
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data by Martines-Corral et al. challenges the dogma of the exclusively venous origin 
of the lymphatic vasculature.
The lymphatic growth factor, VEGF-C, and its receptor, VEGFR-3, are required 
for LEC migration during lymphatic development (Karkkainen et al., 2004; Zhang 
et al., 2010). VEGF-C is expressed in the lateral mesoderm of the embryo from E8.5 
onwards acting as a paracrine factor forming a growth factor gradient towards which 
the nascent LECs expressing VEGFR-3 and its coreceptor Nrp2 migrate from the 
CV (Karkkainen et al., 2004). Lymphatic regulators Coup-TFII and Prox1 have both 
been shown to upregulate VEGFR-3 as well as Nrp2 expression (Lin et al., 2010; 
Srinivasan et al., 2010). VEGF-C/VEGFR-3 signaling is further required for the 
subsequent survival, proliferation, migration and sprouting of the LECs to form the 
primitive lymphatic vascular plexus (reviewed in (Alitalo et al., 2005)). VEGFR-3 
is strongly expressed in all developing lymphatic vessels until E17.5 after which 
expression is gradually reduced in maturing collecting lymphatic ducts (Norrmen 
et al., 2009). High expression is maintained in lymphatic valves and capillaries 
(Norrmen et al., 2009). Nrp2 expression is seen in LECs in the CV from E10.0 
onwards (Yuan et al., 2002) and around E11.5 in LECs migrating out of the CV 
(François et al., 2011). 
Separation of blood and lymphatic vasculature: podoplanin
The separation of the nascent lymph sacs from the CV occurs when circulating 
platelets in the CV aggregate at the sites between the LSs and the CV. Two 
haematopoietic intracellular signaling proteins, Syk and Slp76, were first identified 
as regulators of the process, Syk-/- and Slp76-/- mice die perinatally and exhibit 
hemorrhage, blood filled lymphatics and abnormal connections between blood and 
lymphatic vessels (Abtahian et al., 2003). Podoplanin is a lymphatic endothelium 
specific membrane protein that is expressed on LEC precursors in the ballooning 
PLCs and was recently found to be required for the separation. Podoplanin has been 
shown to interact with membrane lectin CLEC-2 expressed on platelets causing 
platelet activation and aggregation both in vitro and in vivo (Uhrin et al., 2010). 
Mouse studies show that podoplanin expression and platelet aggregation is observed 
at the separation sites between nascent lymph sacs and the CV at E12.5 and a 
complete separation is achieved by E14.0. It has been suggested that the separation 
is caused either by the physical barrier formed by the platelet aggregate or through 
release of vasoconstrictive factors that sever the connections (Uhrin et al., 2010). 
Regardless of the exact mechanism, podoplanin is required for successful separation 
as podoplanin deficiency results in lack of platelet aggregation and separation of 
blood and lymphatic vasculatures, as demonstrated by presence of blood filled 
lymphatic vessels in the mutant mice (Uhrin et al., 2010). 
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Lymphatic maturation: Foxc2, ephrinB2 and bone morphogenetic protein 9
Once the primary lymphatic plexus has been formed through sprouting mediated by 
VEGF-C/VEGFR-3/Nrp2 signaling, the plexus needs to be remodeled into a mature 
network consisting of lymphatic capillaries and larger collecting ducts with their 
specialized structures and expression profiles. Transcription factor Foxc2 regulates 
these later maturation events during lymphatic development. In the mesentery, 
uniform Foxc2 expression is detected in developing LECs at E15.5(Norrmen et al., 
2009). Subsequently Foxc2 expression begins to decrease in the collecting ducts 
between E15.5 and E16.5, as they mature and strong expression in only maintained 
in the developing lymphatic valves (Norrmen et al., 2009). The transient expression 
of Foxc2 is required for the formation of both lymphatic collecting ducts and 
lymphatic capillaries. Lack of Foxc2 results in a failure of the putative collecting 
ducts to mature and adopt their proper collecting duct phenotype characterized by 
presence of intraluminal valves, NG2+ mural cell coverage and downregulation of 
Prox1, VEGFR-3 and LYVE1 (Norrmen et al., 2009). Lymphatic capillary network 
formation is also defective in Foxc2-/- mice (Norrmen et al., 2009). Superficial 
lymphatic capillary network forms postnatally through sprouting from pre-collecting 
vessels situated deeper in the tissues. Normal lymphatic capillaries maintain strong 
LYVE1 expression and lack pericyte coverage. Foxc2-/- capillaries exhibit impaired 
sprouting and abnormal recruitment of pericytes around the lymphatic capillaries 
which impairs their function (Norrmen et al., 2009; Petrova et al., 2004). 
Foxc2 cooperates with transcription factor NFATc1 during lymphatic maturation 
(Kulkarni et al., 2009; Norrmen et al., 2009). The expression pattern of NFATc1 
is similar to that of Foxc2 with strongest expression seen in collecting ducts and 
valves (Norrmen et al., 2009). Furthermore, inhibition of nuclear translocation of 
NFATc1 and thus NFATc1 signaling, with cyclosporine A (CsA) results in a very 
similar phenotype to that observed in Foxc2 deficient mice (Norrmen et al., 2009). 
Loss of NFATc1 results in embryonic lethality prior to collecting vessel formation 
thus making a complete analysis impossible, however, at E15.5 NFATc1-/- embryos 
display similar tortuous and widened capillaries reminiscent of those seen in Foxc2 
mutant mice (Norrmen et al., 2009). Treating heterozygous Foxc2 mice with CsA 
results in a significantly more severe lymphatic phenotype compared to wild-
type mice treated with CsA further suggesting that the two regulators cooperate 
during lymphatic maturation (Norrmen et al., 2009). The signal required for Foxc2 
upregulation at E15.5 remains to be determined, however, it is known that Prox1 
induces NFATc1 expression, while VEGF-C mediated activation of VEGFR-2 induces 
nuclear translocation of NFATc1 (Norrmen et al., 2009).
EphrinB2 and bone morphogenetic protein 9 (BMP9) have also been implicated 
in remodeling of the primary lymphatic plexus and collecting vessel maturation 
(Levet et al., 2013; Makinen et al., 2005). Mice lacking the C-terminal PDZ-
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interaction domain of ephrinB2 display a phenotype similar to both Foxc2 and 
NFATc1 mutant mice. These mutants display hyperplastic collecting ducts that 
lack valves and maintain LYVE1 expression while the lymphatic capillaries show 
abnormal mural cell recruitment and a sprouting defect (Makinen et al., 2005). 
These phenotypes suggest misspecification of the lymphatic structures, that is, 
that both lymphatic collecting ducts and capillaries failed to acquire their distinct 
phenotypes. BMP9-/- mice display a similar phenotype with enlarged lymphatic 
capillaries and collecting ducts that maintain LYVE1 expression and lack valves 
(Levet et al., 2013). Interestingly, BMP9 was also shown to inhibit LYVE1 and induce 
Foxc2, Cx37 and ephrinB2 expression in vitro, suggesting that BMP9 mediates 
some of its effects by regulating the expression of these lymphatic regulators (Levet 
et al., 2013).
3. LYMPHATIC VALVES
EMBRYONIC DEVELOPMENT AND REGULATORS OF VALVE MORPHOGENESIS
Larger caliber lymphatic vessels (pre-collecting and collecting ducts) contain 
intraluminal valves that ensure unidirectional flow of the lymph. Lymphatic valves 
consist of two leaflets that are responsible for opening and closing the valve thus 
regulating flow in lymphatic vessels. The valve leaflets are made up of an ECM core 
surrounded by specialized LECs anchored to the core. In mice, lymphatic valve 
morphogenesis begins at E15.5 and four stages of valve formation can be observed 
(Figure 6) (Sabine et al., 2012). During the initiation phase, LECs expressing high 
levels of transcription factors Prox1 and Foxc2 cluster at the putative valve sites. Next, 
in the condensation phase around E16.5, constriction of the lymphatic vessels at the 
sites of valve formation is observed as the valve-forming LECs arrange themselves 
into ring-like structures and begin to lay down ECM core components, collagen 
type IV, laminin α5 and fibronectin splice variant EIIIA (FN-EIIIA). During the 
elongation phase the secretion of valve ECM components increases as the leaflet core 
matrix is assembled. Simultaneously, the valve-forming LECs reorient, elongate, 
migrate along and attach themselves to the forming leaflet core through upregulation 
of integrin-α9, which anchors the valve-forming LECs to the core matrix. During 
the maturation stage, the valve-forming LECs penetrate into the vessel lumen and 
form mature valve leaflets (reviewed in (Sabine and Petrova, 2014)). Lymphatic 
valve morphogenesis is completed during the first postnatal days and functional 
valves are required throughout life to prevent backflow of fluid that can often be 
associated with lymphedema.
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Figure 6. Stages of lymphatic valve morphogenesis. Valve morphogenesis initiates around E15.5 by 
clustering of Prox1high/FOCX2high LECs. During condensation phase valve-forming LECs form ring-like 
valve sites. This phase is accompanied by upregulation of gap-junction protein connexin37 (Cx37), which 
is thought to guide the process. In elongation phase valve-forming LECs reorient, elongate and start 
invaginating into vessel lumen forming the valve leaflets. Valve leaflet formation requires integrin α9 and 
fibronectin splice variant EIIIA (FNEIIIA). Valve morphogenesis is concluded by birth. Adapted from Sabine 
et al. 2012. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin 
during lymphatic valve formation. Dev. Cell; 14;22(2):430-45. Copyright license number 3620311229274.
The current model of lymphatic valve formation proposes that fluid flow, together 
with molecular regulators, control the process of valve morphogenesis. Mechanical 
forces imitating flow have been shown to induce Cx37 expression, NFATc1/
calcineurin signaling and cytoskeletal changes associated with valve-LECs in vitro, 
suggesting that flow controls the expression of valve regulators (reviewed in (Sabine 
and Petrova, 2014)). In addition, in vivo experiments suggest that initiation of valve 
formation in the mesenteric lymphatics correlates with the onset of lymph flow 
(Sabine et al., 2012). Furthermore, valves are often situated in vessel branch points 
and other sites with disturbed flow (Sabine et al., 2012; Wang and Simons, 2014). 
Together these data demonstrate that flow regulates both valve gene expression 
and helps determine the positions where valve morphogenesis takes place.
Clustering of Prox1high/Foxc2high valve-forming LECs is followed by an 
upregulation of gap-junction protein connexin 37 (Cx37) and nuclear accumulation of 
transcription factor NFATc1 in these valve-forming LECs. The induction of Cx37 and 
NFATc1 signaling is triggered by flow in cooperation with Prox1 and Foxc2 (Sabine 
et al., 2012). High Prox1 levels are required for development of lymphovenous 
valves (Srinivasan and Oliver, 2011). Lymphatic valve-forming LECs express higher 
levels of Prox1 than ductal LECs implying that high levels of Prox1 might also be 
required for lymphatic valve formation. However, the exact significance of high 
Prox1 expression observed in valve-LECs remains to be determined although Prox1 
Prox1
Integrin α9
L
Figure 6. Stages of lymphatic valve morphogenesis. Valve morphogenesis initiates around E15.5 by clustering of
Prox1high/FOCX2high LECs. During condensation phase valve-forming LECs form ring-like valve sites. This phase is
accompanied by upregulation of gap-junction protein con exin37 (Cx37), which is thought to guide the process. In
elongation phase v lve-forming LECs reorient, elongate and start invaginating into vessel lum n forming the valve
leaflets. Valve leaflet formation requires integrin α9 and fibronectin splice variant EIIIA (FNEIIIA). Valve
morphogenesis is concluded by birth. Adapted from Sabine et al. 2012. Mechanotransduction, PROX1, and FOXC2
cooperate to control connexin37 and calcineurin during lymphatic valve formation. Dev. Cell; 14;22(2):430-45.
Copyright license number 3620311229274.
E15.5 E16.5 E17.5 E18.5- P0
Cx37 Integrin α9  FNEIIIAProx1 
FOXC2
E18.5
Pr
ox
1
La
m
in
in
α5 A
27
has been shown to induce several genes necessary for valve formation including 
Foxc2, Cx37, integrin-α9 and VEGFR-3 in vitro (Mishima et al., 2007; Sabine et 
al., 2012) Interestingly, Prox1 and Foxc2 are not uniformly expressed in all valve-
forming LECs: cells upstream of the developing valves are Prox1high/Foxc2low while 
the cells downstream are Prox1low/Foxc2high (Sabine et al., 2012). The significance 
of the differential expression is unknown but it has been hypothesized that it could 
determine the direction of the future valve leaflets (Sabine et al., 2012). 
Both Foxc2-/- and Cx37-/- mice display a dramatic reduction in number of valves 
proving their importance for valve morphogenesis (Kanady et al., 2011; Norrmen et 
al., 2009). Interestingly, Foxc2-/- mice have no detectable Cx37 expression suggesting 
that lack of Cx37 is at least partially the cause for defective valve formation observed 
in Foxc2-/- mice (Sabine et al., 2012). Cx37 regulates cell-cell communication at 
cell junctions and it has been suggested that the role of Cx37 is to help guide the 
clustered valve-forming LECs into more organized ring-like structures seen after 
the initiation phase. Supporting this hypothesis, valve formation arrests after the 
initiation phase and no ring-like structures are seen in Cx37-/- mice (Kanady et al., 
2011; Sabine et al., 2012). Inhibition of NFATc1/calcineurin signaling via CsA results 
in reduction of lymphatic valves (Norrmen et al., 2009). Furthermore, endothelial 
loss of calcineurin regulatory subunit Cnb1 (Cnb1ecKO) inhibits the formation of well-
defined valve territories with distinct boundaries between Prox1high and Prox1low cells 
(Norrmen et al., 2009; Sabine et al., 2012). The subsequent elongation phase was 
also disrupted in Cnb1ecKO mice, as the valve-forming LECs failed to reorient and 
invaginate into the vessel lumen (Norrmen et al., 2009). Together these defects 
caused a significant reduction in the amount of mature valves observed in these mice 
and the valve structures that were present were poorly formed as their development 
had arrested (Sabine et al., 2012). 
The elongation phase is characterized by increased leaflet core ECM component 
deposition and integrin-α9 expression in the valve-forming LECs as they invaginate 
into the vessel lumen. Some laminin α5 deposition is seen already at the initiation 
phase, however the expression becomes increasingly pronounced as valve 
morphogenesis progresses (Sabine et al., 2012). Deposition of fibronectin splice 
variant EIIIA (FN-EIIIA) coincides with the onset of expression of its receptor, 
integrin-α9, on valve-forming LECs around E16.5-E17 (Bazigou et al., 2009). FN-
EIIIA/integrin-α9 signaling during the elongation phase is required for leaflet core 
matrix assembly and leaflet elongation (Bazigou et al., 2009). Embryonic endothelial-
specific loss of Itga9 (encoding integrin-α9) results in underdeveloped valve leaflets 
with disorganized matrix core and a similar, although milder, phenotype is seen in 
FN-EIIIA deficient mice (Bazigou et al., 2009).
Valve maturation occurs from E18.5 to early postnatal days (Norrmen et al., 
2009; Sabine et al., 2012). Mature valves have two leaflets that are sufficiently 
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elongated to successfully close the valve and prevent retrograde flow of the lymph. 
Mature leaflets consist of an organized, thick ECM core. Strong expression of Prox1, 
Foxc2, Cx37 and integrin-α9, as well as active calcineurin signaling are maintained 
in LECs in mature valves (Bazigou et al., 2009; Norrmen et al., 2009; Sabine et al., 
2012). Postnatal lymphatic inactivation of Cnb1 results in regression of the leaflet 
ECM core indicating that it is required for valve maintenance (Norrmen et al., 2009). 
FN-EIIIA/integrin-α9-interaction seems to be dispensable for valve maintenance 
as the defects observed in FN-EIIIA-/- mice gradually diminish postnatally and a 
transient postnatal inactivation of Itga9 does not result in valve leaflet regression 
(Bazigou et al., 2009; Sabine et al., 2012).
Developing and mature valves express high levels of VEGFR-2, VEGFR-3 and 
ephrinB2 (Makinen et al., 2005; Wirzenius et al., 2007). The function of VEGFR-2 
and VEGFR-3 in lymphatic valves is largely undetermined. However, VEGF-C/
VEGFR-2 signaling has been shown to induce nuclear translocation of NFATc1, 
which is required for both embryonic valve formation and postnatal maintenance 
(Norrmen et al., 2009), while VEGFR-3 has been suggested to cooperate with Foxc2 
during lymphatic collecting duct maturation, during which valve formation also 
occurs (Petrova et al., 2004). Mutant mice lacking the C-terminal PDZ interaction 
domain of ephrinB2 (ephrinB2ΔV/ΔV) display a complete lack of lymphatic valves 
(Makinen et al., 2005). Although the function of ephrinB2 in lymphatic valves 
is currently poorly understood, it has been shown to regulate internalization of 
VEGFR-3 and therefore ephrinB2 could modulate valve formation via affecting 
VEGFR-3 (Wang et al., 2010).
4. REGULATORS OF ANGIOGENESIS AND LYMPHANGIOGENESIS
VASCULAR ENDOTHELIAL GROWTH FACTORS AND THEIR RECEPTORS
Vascular endothelial growth factors (VEGFs) and their receptors are key regulators of 
endothelial cell function during vasculogenesis, angiogenesis and lymphangiogenesis. 
The mammalian family of vascular endothelial growth factors consists of five secreted 
glycoproteins VEGF-A (VEGF), VEGF-B, VEGF-C, VEGF-D and placenta growth 
factor (PlGF) that bind to their cognate vascular endothelial growth factor receptors 
(VEGFR) 1, 2 and 3. VEGFRs are mainly expressed in endothelial cells although 
expression is seen in some other cell types, especially in cells of the hematopoietic 
lineage (Olsson et al., 2006). VEGFR-2 and VEGFR-3 signaling can promote both 
angiogenic and lymphangiogenic processes depending on developmental stage 
and context. However, VEGFR-2 most commonly induces angiogenic activity in 
BECs while VEGFR-3 is the main regulator of lymphangiogenesis in LECs. Instead 
29
of promoting, VEGFR-1 restricts and modulates the angiogenic response (Ho et 
al., 2012) and recruits macrophages to the sites of tissue remodeling (Pipp et al., 
2003). VEGFRs are transmembrane tyrosine kinase receptors that are composed 
of extracellular immunoglobulin (Ig) homology domains, a transmembrane domain 
and a C-terminal intracellular (IC) tyrosine kinase domain. Different VEGFR Ig 
domains convey ligand specificity and regulate dimerization and phosphorylation 
of the IC tyrosine residues. Upon binding of a dimeric VEGF ligand, receptor 
dimerization and autophosphorylation takes place followed by phosphorylation 
of the intracellular phosphorylation sites by other cytoplasmic tyrosine kinases 
(Koch et al., 2011). This triggers downstream signaling cascades eventually 
affecting endothelial cell behavior such as survival, proliferation, migration and 
sprout formation (Koch et al., 2011). The vascular endothelial growth factors have 
multiple isoforms that are created through alternative splicing and posttranslational 
processing. Different isoforms have different diffusion rates and receptor binding 
affinities. The VEGFs also interact with several integrins and neuropilins that have 
been shown to associate with VEGF receptors and modulate their function (reviewed 
in (Jeltsch et al., 2013; Tammela et al., 2005)). 
VEGF and VEGFR-2
VEGF (VEGF-A) signaling mediated by VEGFR-2 (also known as Flk1 and KDR) 
is the main inducer of angiogenesis both embryonically and postnatally and 
promotes EC survival, proliferation, migration and sprouting as well as vascular 
permeability (de Vries et al., 1992; Gille et al., 2001; Hiratsuka et al., 1998; Quinn et 
al., 1993) (reviewed in (Ferrara and Kerbel, 2005)). Genetic deletion of VEGF leads 
to defects in blood island formation, EC development and subsequent embryonic 
lethality at E8-E9 (reviewed in (Ferrara et al., 2003)). Loss of just one copy of 
VEGF results in death at E11-E12 due to vascular defects demonstrating that the 
requirement of VEGF protein is dosage sensitive (Carmeliet et al., 1996; Ferrara et 
al., 1996). VEGF is first expressed in the anterior parts of the embryo and it guides 
the migration and organization of VEGFR-1 and VEGFR-2 expressing cells during 
vascular morphogenesis (Hiratsuka et al., 2005). VEGFR-2 is also indispensable for 
vascular development; Vegfr2 knockout mice die at E8.5-9.5 and display a complete 
lack of vasculogenesis and hematopoiesis (Shalaby et al., 1995). VEGFR-2 becomes 
downregulated in mature blood vessels but low level autocrine VEGF/VEGFR-2 
signaling has been shown to be necessary for vascular integrity even in quiescent 
vasculature (Lee et al., 2007). VEGFR-2 can also bind the processed form of VEGF-C 
and is expressed in the lymphatic endothelium (Joukov et al., 1996; Joukov et al., 
1997). Activation of VEGFR-2 signaling in the lymphatics causes circumferential 
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growth of lymphatic vessels but is unable to induce lymphatic sprouting (Nagy et 
al., 2002; Saaristo et al., 2002; Wirzenius et al., 2007).
Six VEGF isoforms consisting of different amount of amino acids have been 
identified in humans: VEGF121, VEGF145, VEGF165, VEGF183, VEGF189 and VEGF206 
(reviewed in (Ferrara et al., 2003; Robinson and Stringer, 2001)). Of these, VEGF121, 
VEGF165 and VEGF189 are the major variants expressed by most cell types (reviewed 
in (Robinson and Stringer, 2001)). In mice, three splice variants have been identified: 
VEGF120, VEGF164 and VEGF188. The isoforms display different diffusion rates, as 
the larger variants bind to the ECM heparan sulfate proteoglycans (HSPGs) with 
greater affinity than the smaller ones (reviewed in (Ferrara et al., 2003)). Therefore 
the isoforms have different biological functions, which has been demonstrated by 
distinct phenotypes observed in VEGF isoform-specific knockout mice (Carmeliet et 
al., 1999; Stalmans et al., 2002). VEGF has also been shown to bind to Nrp1 and Nrp2 
which act as coreceptors for VEGFRs (Gluzman-Poltorak et al., 2000; Soker et al., 
2002). A soluble version of the VEGFR-2 (sVEGFR-2) lacking the transmembrane 
and intracellular domains is produced through alternative splicing (Albuquerque 
et al., 2009). sVEGFR-2 functions as a natural inhibitor of lymphangiogenesis 
by sequestering VEGF-C (Albuquerque et al., 2009). It was shown to be highly 
expressed in the cornea and be required for maintenance of the alymphatic cornea, 
similar to the way that sVEGFR-1 maintains corneal avascularity (Ambati et al., 
2006). In addition, sVEGFR-2 expression was detected in the epidermis and hair 
follicles and it was shown to modulate postnatal growth of peripheral lymphatic 
capillaries (Albuquerque et al., 2009). Interestingly, sVEGFR-2 was also shown 
to be present in circulation, bind VEGF and promote mural cell association with 
vascular endothelium and vessel maturation (Lorquet et al., 2010). 
VEGF expression is strongly induced in hypoxic conditions by hypoxia inducible 
factor α1 (HIF- α1) (reviewed in (Pugh and Ratcliffe, 2003)). HIF-α1 is rapidly 
degraded in normoxic conditions but becomes stabilized under hypoxia. HIF-α1 
then heterodimerizes with HIF-β1 and binds to hypoxia-response elements on VEGF 
promoter to induce expression (reviewed in (Pugh and Ratcliffe, 2003)). Subsequent 
secretion and diffusion of VEGF forms a gradient and activates ECs via VEGFR-2 
on the already existing vessels to initiate sprouting towards the hypoxic tissue thus 
providing a new blood supply (Gerhardt et al., 2003; Ng et al., 2006). In sprouting 
angiogenesis, VEGF also induces the formation of tip cells that via expression of 
VEGFR-2 sense the VEGF gradient and lead the growing sprout towards the source 
of the growth factor (Gerhardt et al., 2003). This process has been extensively studied 
during postnatal vascularization of the mouse retina where VEGF gradient guides 
the neovessel growth from the optic nerve towards the retinal periphery. VEGF/
VEGFR-2 signaling promotes angiogenesis in pathological settings as well. VEGF 
expression has been shown to drive tumor angiogenesis and growth as well as 
excessive vascular growth seen in retinopathies (reviewed in (Jeltsch et al., 2013)).
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VEGF-B and PlGF
VEGF-B and PlGF are ligands for VEGFR-1 and Nrp1 (Olofsson et al., 1996; Persico 
et al., 1999). VEGF-B is expressed in striated muscle, myocardium and brown fat 
while PlGF is predominantly present in the placenta, heart and lungs (reviewed in 
(Olofsson et al., 1999; Salven et al., 1998)). The exact roles of these growth factors 
are still being studied. VEGF-B is a poor inducer of angiogenesis; however, it has 
been shown to regulate fatty acid uptake by ECs and thus their lipid metabolism 
(Hagberg et al., 2013). PlGF induces angiogenesis in various tissues although this 
may at least partially be due to heterodimerization with VEGF. VEGF-B knockout 
mice display slightly smaller hearts in one genetic background but otherwise VEGF-B 
and PlGF deficient mice display no obvious vascular, - or other, phenotype and have 
a normal lifespan indicating that both growth factors are dispensable for embryonic 
development (Bellomo et al., 2000). However, studies suggest that VEGF-B and 
PlGF might play a role in revascularization during pathological settings, especially 
during recovery from ischemic episodes (Bellomo et al., 2000; Carmeliet et al., 
2001; Li et al., 2008; Luttun et al., 2002). In addition, VEGF-B has been shown 
to induce coronary artery growth in rats (Bry et al., 2010) while PlGF promotes 
wound healing (Failla et al., 2000; Kagawa et al., 2009). VEGF-B does not have an 
obvious function in tumor biology while PlGF has been suggested to drive tumor 
angiogenesis and growth in several tumor models although its function seems to 
be context-dependent (reviewed in (Bry et al., 2014)).
VEGFR-1
VEGFR-1 (Flt-1) binds VEGF, VEGF-B and PlGF with high affinity, however, ligand 
binding results only in weak tyrosine kinase activity (Fong et al., 1995; Huang 
et al., 2001). VEGFR-1 can form heterodimers with VEGFR-2 which leads to 
unique downstream signaling events different from both VEGFR-1 and VEGFR-2 
homodimers (Huang et al., 2001). VEGFR-1 is expressed in ECs and macrophages, 
and it has been shown to recruit macrophages to the sites of inflammation (Zachary 
and Gliki, 2001). VEGFR-1 deficient mice die at E8.5 due to disorganization of the 
developing vasculature and endothelial cell overgrowth (reviewed in (Ferrara et al., 
2003; Fong et al., 1995)). In certain settings, loss of VEGFR-1 postnatally results 
in increased angiogenesis as well (Ho et al., 2012). Interestingly, mice expressing a 
truncated form of the receptor lacking the intracellular signaling domain are viable 
and only display a mild phenotype (Hiratsuka et al., 1998; Niida et al., 2005; Sawano 
et al., 2001). These data suggest that VEGFR-1 signaling is dispensable and that 
VEGFR-1 mainly functions as a decoy receptor to sequester excessive VEGF and 
thus modulate angiogenesis. Mechanistically, in the absence of VEGFR-1, more 
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VEGF is available to bind and activate VEGFR-2, which promotes angiogenesis 
(Ho et al., 2012). Interestingly, in addition to limiting angiogenesis, VEGFR-1 has a 
pro-angiogenic function in vascular sprout formation and guidance from the dorsal 
aorta (DA) during embryonic development, evident by decreased intersomitic sprout 
formation seen in flt-1-/- embryos (Kearney et al., 2002). In addition to membrane-
tethered form, a soluble form of VEGFR-1 (sVEGFR-1) consisting of the extracellular 
domain is produced through alternative splicing (Shibuya, 2001). sVEGFR-1 has 
been shown to inhibit VEGF induced angiogenesis, promote vessel maturation 
through mural cell recruitment and maintain avascularity of the cornea (reviewed 
in (Ferrara et al., 2003)) (Ambati et al., 2006; Lorquet et al., 2010). As VEGFR-1 is 
an inhibitor of angiogenesis it has not been indicated in tumor progression, however, 
it might play a role in other pathologies. Most notably, elevated circulating sVEGFR-1 
levels are seen in pre-eclampsia, a condition characterized with hypertension and 
proteinuria (Levine et al., 2004; Maynard et al., 2003).
VEGF-C, VEGF-D and VEGFR-3
VEGFR-3 (Flt4) is the main mediator of LEC survival, proliferation, migration and 
sprouting, but it is also necessary for embryonic vascular development (Dumont et 
al., 1998). VEGFR-3 is expressed by all ECs during early development but expression 
is downregulated, first in arteries then veins and finally expression is largely restricted 
to the lymphatic endothelium by birth (Kaipainen et al., 1995). In adults, the only 
BECs expressing VEGFR-3 are those forming fenestrated blood vessels found in 
endocrine organs and blood vessels in the peri-implantation uterus (Douglas et al., 
2009; Partanen et al., 2000). In addition, tumor blood vessels have been shown 
to express VEGFR-3.VEGFR-3 binds VEGF-C and VEGF-D and both factors are 
proteolytically processed to increase their affinity to their receptors (Achen et al., 
1998). Processing increases their affinity to VEGFR-3 while only fully processed, 
mature forms bind to VEGFR-2 (Achen et al., 1998; Joukov et al., 1997). VEGF-C 
transcripts are induced by multiple growth factors, pro-inflammatory cytokines as 
well as environmental stress signals, but not hypoxia (Cohen et al., 2009; Enholm 
et al., 1997). Unlike human VEGF-D, mouse VEGF-D does not bind to VEGFR-2 
(Baldwin et al., 2001). Embryonically, VEGF-C expression is seen at the sites of 
lymph sac formation and later associated with lymphatic sprouting (Karkkainen et 
al., 2004; Kukk et al., 1996). Two VEGF-D splice variants exist and most prominent 
expression is seen in the heart, lung, skeletal muscle and the small intestine (Achen 
et al., 1998; Avantaggiato et al., 1998; Baldwin et al., 2001).
Vegfc-/- mice lack all lymphatic structures and die prior to birth and even Vegfc+/- 
mice display chylous ascites and lymphatic hypoplasia at birth (Karkkainen et al., 
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2004). On the other hand, deletion of Vegfd only results in a mild phenotype 
with reduced lymphatic vessel density in the bronchioles (Baldwin et al., 2005). 
Indeed, deletion of both Vegfc and Vegfd recapitulates the phenotype seen in 
Vegfc-/- mice with no additional defects caused by deletion of Vegfd (Haiko 
et al., 2008). Even though Vegfd is not sufficient to compensate for the loss of 
Vegfc, Vegfd overexpression has been shown to promote both angiogenesis and 
lymphangiogenesis in vivo (Baluk et al., 2005; Bhardwaj et al., 2003; Byzova et 
al., 2002; Rissanen et al., 2003). 
Vegfr3 deficient mice die by E10.5, prior to lymphatic development, due to defects 
in remodeling of the primary vascular plexus into a more hierarchical structure 
and impaired hematopoiesis (Dumont et al., 1998; Hamada et al., 2000). Vegfr3 
mutant mouse lacking the ligand-binding domain (LBD) or with an inactivating 
mutation in the kinase domain (TKmut) of the protein have enabled the study 
of its role in embryonic lymphatic development (Zhang et al., 2010). Embryos 
with mutated kinase domain lacked all lymphatic structures and developed severe 
edema. Interestingly, lymph sac formation was observed in mice that lacked the 
LBD of VEGFR-3 even though lymph sacs do not form in absence of VEGF-C. Also, 
blood vascular development was normal in both mutants suggesting that neither 
ligand binding nor kinase activity of VEGFR-3 is indispensable for angiogenesis 
(Zhang et al., 2010). A possible explanation to these phenotypes is that since both 
VEGFR-3 mutant proteins are still able to form heterodimers with VEGFR-2, ligand 
binding to VEGFR-2 could activate VEGFR-3 signaling in heterodimers and thus 
promote early blood vascular development and also lymph sac formation (Zhang 
et al., 2010). Furthermore, Nrp2 binds VEGF-C and could therefore indirectly 
activate VEGFR-3 signaling (Karpanen et al., 2006a; Zhang et al., 2010). It has 
also been shown that loss of both VEGF-C and VEGF-D does not cause defects 
in blood vascular development even though they are the only known ligands of 
VEGFR-3, raising the possibility that another ligand exists (Haiko et al., 2008). It 
has also been suggested that VEGFR-3 is capable of ligand-independent signaling 
in addition to ligand-dependent activation, and that the different signaling types 
have different downstream effects (Tammela et al. 2011). Indeed, data by Tammela 
et al. demonstrated that VEGFR-3 phosphorylation could occur in the absence of 
ligands in vitro (Tammela et al. 2011). Furthermore, postnatal endothelial-specific 
deletion of Vegfr3 caused a hypersprouting phenotype, while previous data showed 
that VEGFR-3-blocking antibodies suppressed angiogenic sprouting in the neonatal 
murine retina (Tammela et al. 2008, Tammela et al. 2011). They hypothesized 
that in the presence of VEGFR-3 blocking antibodies ligand-independent signaling 
still occurs, which induces Notch signaling and inhibits sprouting (Tammela et al. 
2011). In contrast, deletion of Vegfr3 impairs both ligand-dependent and ligand-
independent signaling resulting in decreased Notch signaling and hypersprouting 
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(Tammela et al. 2011).  Mature lymphatic vessel survival appears to not require 
VEGFR-3 signaling as treatment with a VEGFR-3 blocking antibody has no effect 
on established lymphatic vasculature and only blocks formation of new lymphatic 
vessels (Karpanen et al., 2006b; Pytowski et al., 2005).
NEUROPILINS
Neuropilin1 and 2 are transmembrane glycoprotein receptors with a large 
extracellular domain and a short intracellular domain that have no independent 
signaling activity (Kolodkin et al., 1997). In neural cells during axon guidance, 
neuropilins bind class III semaphorins and function as coreceptors for Plexin 
signaling mediating repulsive guidance cues and both Nrp1-/- and Nrp2-/- mutant 
mice display defects in cranial nerve guidance (Chen et al., 2000; Giger et al., 
2000; Kitsukawa et al., 1997). In the vasculature, neuropilins bind VEGFs and act 
as coreceptors for VEGFRs and appear to mediate attractive guidance cues. Nrp1 
associates with all three VEGFRs and is capable of binding VEGF165, VEGF-B167, 
VEGF-B168, PlGF-2, VEGF-C and VEGF-D while Nrp2 interacts with VEGFR-1 and 
VEGFR-3 and binds VEGF145, VEGF165, PlGF-2, VEGF-C and VEGF-D (reviewed in 
(Bagri et al., 2009)), (Gluzman-Poltorak et al., 2000; Kolodkin et al., 1997; Makinen 
et al., 1999; Neufeld et al., 2002; Soker et al., 1998). Nrp1 deficiency leads to defects 
in arterial differentiation, heart development and death by E14 while inhibition 
of Sema3A/Nrp1 signaling during development with blocking antibodies results 
in impaired lymphatic collecting duct maturation and abnormal lymphatic valve 
morphology (Gerhardt et al., 2004; Jurisic et al., 2012; Kawasaki et al., 1999). 
Mice lacking Nrp2 are viable and display only a transient lymphatic phenotype 
during development (Yuan et al., 2002). The distinct phenotypes observed reflect 
the angiogenic versus lymphangiogenic functions for VEGFRs that interact with 
neuropilins. Nrp1 enhances VEGF/VEGFR-2 interactions while Nrp2 has been 
shown to co-internalize with VEGFR-3 upon binding VEGF-C or VEGF-D (Karpanen 
et al., 2006a).
MOLECULAR MECHANISMS REGULATING ENDOTHELIAL CELL –  
VASCULAR MURAL CELL INTERACTIONS 
PDGF-B/PDGFR-β
Platelet-derived growth factor B (PDGF-B) is a secreted growth factor that binds as a dimer 
to platelet derived growth factor receptor β (PDGFR-β). Once secreted, PDGF-B is usually 
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bound to the ECM heparin sulfate proteoglycans through a C-terminal retention motif 
(reviewed in (Andrae et al., 2008)), (Abramsson et al., 2007; Kurup et al., 2006; Ostman 
et al., 1991). PDGFR-β is a transmembrane tyrosine kinase receptor that dimerizes and 
trans-autophosphorylates upon ligand binding to activate downstream signaling cascades
Sprouting endothelial tip cells secrete PDGF-B which binds PDGFR-β 
expressed on mural cells (Gerhardt and Betsholtz, 2003). Binding of PDGF-B to 
PDGFR-β promotes pericyte proliferation and migration to the nascent sprout, 
which subsequently promotes vessel maturation. PDGF-B/ PDGFR-β signaling 
has been shown to be indispensable for pericyte recruitment as genetic or 
pharmacological inhibition prevents pericyte recruitment to most organs (Hellstrom 
et al., 1999; Lindahl et al., 1997). Indeed, both PDGF-B and PDGFR-β deficient 
mice die perinatally due to loss of vascular integrity and subsequent leakage and 
hemorrhaging caused by defective pericyte/VSMC coverage in multiple tissues 
(Hellstrom et al., 1999; Leveen et al., 1994; Lindahl et al., 1998; Soriano, 1994). 
Furthermore, mice expressing a mutated form of PDGF-B lacking the retention 
motif also exhibit impaired pericyte recruitment suggesting that PDGF-B has to be 
either cell membrane or matrix-bound in order to exert its appropriate effects on 
pericytes (Bjarnegard et al., 2004; Enge et al., 2002; Lindblom et al., 2003). Genetic 
deletion of either PDGF-B or PDGFR-β resulted in defective pericyte recruitment 
to the CNS and abnormal vascular permeability, the severity of which was found 
to directly correlate with the extent of pericyte coverage loss (Armulik et al., 2010; 
Daneman et al., 2010). PDGFR-β is also expressed by developing VSMCs and it 
is thought to play a role in VSMC maturation as they are recruited to arteries and 
veins (reviewed in (Armulik et al., 2011)).
Angiopoietin-1/Tie2
Angiopoietin-1 (Ang-1) is a secreted growth factor expressed by perivascular cells 
that binds to the Tie2 receptor tyrosine kinase expressed by endothelial cells (Davis 
et al., 1996; Dumont et al., 1992; Sundberg et al., 2002; Wakui et al., 2006). Both 
Ang1-/- and Tie2-/- mutant mice display cardiac defects, decreased mural cell coverage 
and loss of vessel stability leading to hemorrhaging of the microvasculature, and die 
by E12.5 and E14.5, respectively (Puri et al., 1995; Sato et al., 1995), (reviewed in 
(Gaengel et al., 2009)). The vasculature also shows defective hierarchical organization 
into large and small vessels suggesting impaired remodeling of the primary plexus 
(Patan, 1998; Sato et al., 1995). Ang-1/Tie2 signaling has been thought to mediate 
mural cell-endothelial cell interactions and thus promote vascular maturation and 
stability (Suri et al., 1996). However, recent reports have challenged the idea that loss 
of Ang-1/Tie2 signaling disrupts pericyte recruitment and causes the cardiovascular 
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defects seen in Ang1 and Tie2 mutant mice. Chimeric mice containing both wild-
type and Tie2-/- cells showed normal pericyte recruitment to the Tie2 negative 
endothelium embryonically (Jones et al., 2001). Normal pericyte recruitment was 
also observed in mice carrying signaling deficient Tie2 receptors (Tachibana et al., 
2005). Conditional deletion of Ang1 did not disrupt pericyte recruitment either 
(Jeansson et al., 2011). Overexpression of Ang-1 promotes vascular branching and 
remodeling of an immature vascular plexus demonstrating that Ang-1 functions 
in blood vessel formation (Thurston et al., 2005; Uemura et al., 2002). In light of 
these data it has been suggested that loss of Ang-1/Tie2 signaling causes primarily 
vascular defects and instability and that the loss of mural cell coverage observed 
in Ang1-/- and Tie2-/- mutant mice is secondary to endothelial cell defects. Thus, 
Ang-1 and Tie2 seem to not be directly involved in mural cell recruitment but are 
required for angiogenic sprouting/remodeling of the primary vascular plexus and 
stabilization of the newly formed sprouts (reviewed in (Armulik et al., 2011)). 
THE NOTCH SIGNALING PATHWAY
The mammalian Notch family consists of five Delta/Serrate/Lag-2 (DSL) ligands 
Delta-like1 (Dll1), Delta-like3 (Dll3), Delta-like4 (Dll4), Jagged1 (Jag1) and Jagged2 
(Jag2) that interact with four receptors of the Notch family, Notch1-4. The Notch 
proteins are single-pass transmembrane receptors consisting of an extracellular 
domain and an intracellular signaling domain linked non-covalently. The large 
extracellular domain of Notch consists of 29-36 EGF-like repeats; repeats 11 and 12 
are required for interaction with Notch ligands (Cordle et al., 2008; Hambleton et 
al., 2004; Thomas et al., 1991; Vassin et al., 1987; Wharton et al., 1985). The ligands 
consist of EGF-like repeats similar to Notch with Jag ligands containing 16 and Dll 
ligands 8 or fewer. The Notch ligands also contain a Delta/Serrate/LAG-2 (DSL) 
domain, which is required for interaction and activation of Notch (Glittenberg et 
al., 2006; Henderson et al., 1997). Both Notch ligands and proteins are membrane-
bound and therefore Notch signaling requires cell-cell contact between the ligand-
presenting and receptor-expressing cell (Figure 7). It seems that ligands must 
be membrane-bound in order to efficiently induce Notch signaling as engineered 
soluble ligand molecules have been shown to mostly inhibit Notch signaling by 
competitively binding to the receptors (Dikic and Schmidt, 2010; Hicks et al., 2002). 
However, there are some reports of multimerized ligands able to activate Notch as 
well (Hicks et al., 2002). Ligand binding triggers conformational changes in Notch 
unmasking a cleavage site in the extracellular part. Notch is subsequently cleaved 
by ADAM protease(s) releasing the extracellular domain (Notch-ECD) which, 
together with the ligand, is endocytosed to the ligand-presenting cell (Bozkulak 
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and Weinmaster, 2009; Brou et al., 2000; Hartmann et al., 2002). The Notch 
receptor undergoes a second cleavage by a γ-secretase/presenilin complex, which 
releases the intracellular domain (N1IC) allowing it to translocate into the nucleus 
where it forms a complex with CSL (CBF1/ RBPκj, Suppressor of Hairless, Lag-1) 
and Mastermind-like (MAML). N1IC converts the transcriptional repressor complex 
CSL into a transcriptional activator and subsequently activates gene transcription 
through binding to CSL motifs within the promoters of target genes. Alternatively, 
N1IC/CSL/MAML complex can induce the expression of transcriptional repressors 
of the Hairy enhancer-of-split (HES) and Hairy enhancer-of-split with YRPW motif 
(Hey) families and thus indirectly suppress gene expression (reviewed in (Kopan 
and Ilagan, 2009)). 
Figure 7. The Notch signaling pathway. Notch signaling requires cell-cell contact between the ligand-
presenting and receptor-expressing cell. Upon ligand binding, two proteolytic cleavages take place: first, 
cleavage by ADAM protease(s) releases the extracellular domain and subsequently, cleavage by γ-secretase/
presenilin complex releases the intracellular domain (N1IC). N1IC translocates into the nucleus where it forms 
a complex with CBF1/RBPκj, Suppressor of Hairless, Lag-1 (CSL), Mastermind-like (MAML) and co-activators 
(Co-A), which activates target gene expression.
The Notch signaling pathway is an evolutionary conserved signaling pathway that 
regulates various aspects of embryonic development and tissue regeneration in 
adults. Notch mediates cell-fate decisions in a highly context dependent manner 
and can thus either promote or inhibit proliferation, cell death and activation of 
various differentiation programs through its downstream targets. Notch signaling is 
indispensable for normal embryonic development as well as maintenance of proper 
Figure 7. The Notch signaling pathway. Notch signaling requires cell-cell contact between the ligand-presenting and receptor-
expressing cell. Upon ligand binding, two proteolytic cleavages take place: first, cleavage by ADAM protease(s) releases the
extracellular domain and subseque tly, cleavage by γ-secretase/presenili complex eleases the intra ellular domain (N1IC). N1IC
translocates into the nucleus where it forms a complex with CBF1/RBPκj, Suppressor of Hairless, Lag-1 (CSL), Mastermind-like
(MAML) and co-activators (Co-A), which activates target gene expression.
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cell fates in many adult tissues. Indeed, abnormal expression of Notch ligands and/
or proteins has been implicated in tumor growth and progression and several other 
pathological conditions in humans (reviewed in (Andersson et al., 2011)). 
Notch in blood vasculature
The importance of Notch signaling for mammalian vascular development has been 
demonstrated using several transgenic mouse lines. Blood endothelial cells express 
Notch1, Notch4, Dll1, Dll4 and Jagged1 and Notch1-/-, Dll1-/-, Dll4-/- and Jagged1-/- 
mice die between E9.5 and E12.5 due to vascular remodeling defects (Hrabe de 
Angelis et al., 1997; Krebs et al., 2004; Krebs et al., 2000; Xue et al., 1999). Dll4 
haploinsufficiency causes severe vascular defects and embryonic lethality in certain 
inbred backgrounds indicating that it is required in dosage dependent manner 
for normal vascular development (Duarte et al., 2004; Gale et al., 2004). Notch1 
expression is detected at E7.5 in the embryonic mesoderm and in the endothelium 
from E8.5 onwards. In addition, strong expression is seen in presomitic mesoderm 
and neuroectoderm and Notch1 has been shown to be indispensable for somite 
polarization and segmentation as well as neural development (Conlon et al., 1995; 
Del Amo et al., 1992; Reaume et al., 1992). Notch4 displays an endothelial cell 
specific expression pattern both during development and adulthood (Shirayoshi et 
al., 1997; Uyttendaele et al., 1996). Notch4 null mice display no vascular phenotype 
developmentally suggesting Notch1 is able to compensate for the loss of Notch4 in 
endothelial cells (Krebs et al., 2000). Although Notch4-/- mice do not exhibit a vascular 
phenotype embryonically, loss of Notch4 combined with Notch1 heterozygocity 
or deficiency results in a more severe phenotype than Notch1 heterozygocity or 
loss alone indicating that the two Notch proteins genetically interact (Krebs et 
al., 2000). Postnatally, Notch4 has been implicated in pathological angiogenic 
settings. Overexpression of constitutively active form of Notch4 is associated with 
arteriovenous malformations (Murphy et al., 2014). 
Dll4 has been shown to be the key ligand required for blood vascular development 
in mice (Gale et al., 2004; Krebs et al., 2004; Suchting et al., 2007). Dll4 expression 
is first seen in the dorsal aortae and endocardium at E7 and later during development 
and adulthood in the arterial vasculature where it functions as a ligand for Notch1 
and Notch4 (Shutter et al., 2000). Jagged1 is first detected at E8.5 in endothelial 
cells and heart tube (Lindsell et al., 1995; Myat et al., 1996). Notch1/Dll4 signaling 
has been shown to regulate arterial-venous specification by promoting arterial fate 
(Duarte et al., 2004; Kim et al., 2008; Trindade et al., 2008). Dll1 expression is 
restricted to the arterial endothelium where it is first seen at E13.5, and it is required 
for maintenance of arterial phenotype later in development and postnatally (Lawson 
et al., 2001; Limbourg et al., 2007; Lobov et al., 2007; Sorensen et al., 2009). 
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During sprouting angiogenesis in the postnatal mouse retina, Notch signaling 
functions to limit the number of “tip cells” and thus sprouts that form in response 
to VEGF released by the underlying astrocyte network (Figure 8) (Hellstrom et 
al., 2007). According to the current model, VEGF induces Dll4 expression in tip 
cells which in turn activates Notch signaling in the adjacent endothelial cells and 
through lateral inhibition prevents them from adopting the tip cell fate (Hellstrom 
et al., 2007; Lobov et al., 2007; Suchting et al., 2007). These cells with active 
Notch signaling become “stalk cells” instead, which are more proliferative than 
the chemotactic tip cells guiding the growth of the sprout. Supporting the model, 
it was shown that genetic or pharmacological disruption of Dll4/Notch signaling 
leads to excessive tip cell and sprout formation and increased vascular density in 
the mouse retina (Hellstrom et al., 2007). Although the role of endothelial Jagged1 
is less studied, it seems that Jag1/Notch signaling normally promotes angiogenesis 
as endothelial-specific loss of Jagged1 results in impaired angiogenesis in the mouse 
retina (Benedito et al., 2009). Notch signaling also regulates the expression of VEGF 
receptors and it is thought that the tip and stalk cells display different expression 
profiles due to their different Notch signaling status (Shawber et al., 2007; Suchting 
et al., 2007; Tammela et al., 2008). Tip cells express Dll4 and therefore have no 
or little Notch signaling and express high levels of both VEGFR-2 and VEGFR-3 
making them highly responsive to VEGF (Hellstrom et al., 2007; Tammela et al., 
2008). In the stalk cells, however, Notch signaling suppresses VEGFR-2 and induces 
VEGFR-1 expression making them less responsive to VEGF thus preventing them 
from forming excessive sprouts as loss of VEGFR-1 results in excess tip cell formation 
in the mouse retina (Gerhardt et al., 2003; Shawber et al., 2007; Taylor et al., 2002). 
In addition, Notch1 has been shown to induce ephrinB2, which positively regulates 
internalization of, and therefore signaling through VEGFR-2 (Sawamiphak et al., 
2010). Interestingly, the effect of Notch signaling on VEGFR-3 appears to be more 
context-dependent as it has been shown to both induce and repress VEGFR-3 
expression (Shawber et al., 2007; Tammela et al., 2008), (reviewed in (Benedito 
et al., 2012; Thomas et al., 2013) This may be due to Notch regulating VEGFR-3 
both directly by binding to the VEGFR-3 promoter and indirectly by regulating 
the expression of other factors, such as the Hes and Hey transcription factors, that 
suppress VEGFR-3 expression (Shawber et al., 2007). VEGFR-2 and VEGFR-3 have 
been shown to form heterodimers that preferentially localize in tip cells (Nilsson 
et al., 2010). In conclusion, Notch and the VEGFRs interact in multiple ways to 
regulate sprouting angiogenesis and the working model will definitely need to be 
updated as new data emerge.
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Figure 8. Notch signaling regulates tip cell/stalk cell determination during sprouting angiogenesis. 
Tip cells are specialized endothelial cells that express VEGF receptors and utilize filopodia to detect the 
environmental cues and guide the growing sprout towards the VEGF gradient. Cell situated behind tip 
cells are stalk cells, that are not chemotactic but instead proliferate to ensure the growth of the sprout. 
Blood vessels in a P5 mouse retina visualized with isolectin-B4 (green). Red arrowheads mark filopodia.
Notch in mural cells
Notch signaling between ECs and mural cells as well as between adjacent mural 
cells regulates vascular maturation. Mural cells express Notch1, Notch2, Notch3 and 
Jagged1 and to date Notch3 and Jagged1 have been shown to be required for normal 
mural cell function in vivo (Domenga et al., 2004; Joutel et al., 1996; Kitamoto 
et al., 2005; Liu et al., 2010b; Varadkar et al., 2008; Wang et al., 2012). Global 
Jag1 null mice die due to vascular remodeling defects but mice with endothelial 
specific deletion of Jag1 display defects in VSMC maturation and recruitment 
demonstrating that endothelial Jagged1/VSMC Notch-signaling is crucial for EC/
VSMC interactions and normal VSMC coverage (Benedito et al., 2009; High et al., 
2008). Furthermore, Notch3 expression in VSMCs is induced and maintained by 
endothelial Jagged1 in vitro (Domenga et al., 2004; Liu et al., 2009; Liu et al., 2010b). 
Notch3 deficient mice are viable and display normal mural cell coverage during early 
development; however, postnatal arterial VSMC maturation is impaired resulting 
in abnormal VSMC morphology, enlarged arteries and dysregulated cerebral blood 
flow (Domenga et al., 2004). Furthermore, reduced coverage is seen in the adult 
Notch3-/- retinas suggesting that Notch3 might be important for maintenance of 
mural cell coverage (Liu et al., 2010b). In vitro, both Jagged1 expression and Notch3 
signaling have been shown to induce expression of contractile proteins in VSMCs 
and thus promote maturation towards a contractile phenotype (Liu et al., 2009). 
Figure 8. Notch signaling regulates tip
cell/stalk cell determination during
sprouting angiogenesis. Tip cells are
specialized endothelial cells that express
VEGF receptors and utilize filopodia to
detect the environmental cues and guide the
growing sprout towards the VEGF gradient.
Cell situated behind tip cells are stalk cells,
that are not chemotactic but instead
proliferate to ensure the growth of the sprout.
Blood vessels in a P5 mouse retina visualized
with isolectin-B4 (green). Red arrowheads
mark filopodia.
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In addition, both Notch1 and Notch3 have been shown to induce expression of 
PDGFR-β in cultured VSMCs although only N1IC was shown to bind directly to 
the promoter of PDGFR-β (Jin et al., 2008).
In humans, mutations in NOTCH3 cause CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy), a 
lethal adult-onset condition characterized by loss of cerebral mural cell coverage 
and subsequent vessel instability, which leads to repeated small strokes (Joutel et 
al., 1996).  On cellular level, granular osmiophilic material (GOM) and NOTCH3 
extracellular domain have been shown to accumulate in the cell membrane of 
VSMCs, which is thought to gradually cause degeneration and loss of the VSMCs 
in the brain (reviewed in (Ayata, 2010; Joutel and Tournier-Lasserve, 2002)). In 
mice, both loss and ectopic expression of Notch1 and Notch4 in the endothelium 
have been associated with arteriovenous malformations (AVMs) (Krebs et al., 2004; 
Krebs et al., 2010). AVMs cause arterial blood to flow directly into veins through 
shunts, thus bypassing the capillary plexus, which leads to high blood pressure 
in veins and an increased risk of hemorrhaging. Interestingly, brain AVMs and 
venous malformations display disorganized and reduced αSMA positive mural 
cell coverage suggesting that defective mural cell recruitment or function might 
contribute to the formation of vascular malformations (Chen et al., 2013; Walker 
et al., 2011). Both Notch1 and Notch3 are expressed in mural cells and Notch3 
has already been implicated in mural cell function in vivo, however, the possible 
role of Notch1 or genetic interaction with Notch3 in regulating mural cell biology 
remains to be determined. 
Notch in lymphatic vasculature
Although Notch has been more extensively studied in the blood vasculature, 
more recent work has showed that Notch also regulates lymphatic endothelial cell 
functions, such as lymphangiogenic sprouting in physiological and pathological 
settings. Notch1 and Notch4 are expressed in some lymphatic vessels in mice, 
as well as extratumoral lymphatics in humans (Shawber et al., 2007). Work by 
Geudens et al. in zebrafish first demonstrated that a decrease in Dll4 levels or its 
receptors Notch-1b or Notch-6 resulted in reduced lymphatic sprouting in zebrafish 
(Geudens et al., 2010). Subsequently, two groups working with mice published their 
opposing results leaving the function of Notch in murine lymphatic development 
somewhat undetermined. Niessen et al. demonstrated that inhibition of Notch 
signaling by blocking antibodies against Notch1 or Dll4 lead to defective lymphatic 
sprouting postnatally and wound healing thus concluding that Notch promotes 
lymphangiogenesis (Niessen et al., 2011). On a molecular level, inhibition of Notch 
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reduced LYVE1 expression in cultured HDLECs and ephrinB2 expression in vivo 
but had no effect on VEGFR-3 (Niessen et al., 2011). On the other hand, Zheng 
et al. generated and utilized a Dll4 decoy (Dll4-Fc) to inhibit Notch signaling and 
showed that treatment with the decoy stimulated postnatal lymphatic sprouting 
suggesting that Notch normally functions to limit lymphangiogenesis the same way 
Dll4/Notch1 signaling has been shown to limit angiogenic sprouting (Hellstrom et 
al., 2007; Zheng et al., 2011). Dll4-Fc treatment did not affect VEGFR-2 or VEGFR-3 
expression levels in cultured HDLECs although a reduction in ephrinB2 levels 
was detected (Zheng et al., 2011). Authors of both reports hypothesize that Notch 
regulates lymphatic sprouting through indirect regulation of VEGFRs but do not 
identify the mechanism. Therefore, further studies are required to elucidate the 
effect of Notch on postnatal lymphangiogenesis. Furthermore, to date, the function 
of Notch during different steps of embryonic lymphatic specification has not been 
studied in mice. 
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Aims of the study
As Notch regulates cell-fate determination in multiple settings during development 
and is a key regulator of blood vascular development, we sought to define roles 
of Notch signaling in regulating specification events during embryonic lymphatic 
development. Mural cells express both Notch1 and Notch3 and Notch3 is known 
to be necessary for mural cell function although the exact mechanism remains to 
be determined. We thus conducted evaluations to elucidate the role of Notch in 
endothelial cell-mural cell interactions during postnatal angiogenesis.
The specific aims were:
I. To investigate the possible role of Notch1 during early lymphatic specification.
II. To study the possible function of Notch signaling in valve morphogenesis.
III. To determine the role of Notch in vascular smooth muscle cells during sprouting 
angiogenesis
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Materials and methods used are described below. Transgenic mouse lines are listed 
in Table 1 with the original references. Antibodies and the applications they were 
utilized in are listed in Table 2. Cell lines are listed in Table 3 and adenoviruses in 
Table 4. The publications in which mouse lines, antibodies, cell lines and viruses 
were used are indicated with Roman numerals.
Table 1. Mouse lines
Mouse line Description Source or Reference Used in
C57BL/6 Inbred laboratory mouse strain NCI II, IV
Notch1+/-
Notch1 disrupted by neo cassette insertion 
into exon coding for EGF repeat 32
(Swiatek et al., 1994) I, III
Notch1fl/fl
Exon 1 flanked by loxP sites and deleted 
after cre expression resulting in gene 
inactivation
(Yang et al., 2004)/ 
JAX Labs
I, II
N1IC
Transgene expressing Notch1-IC preceded 
by a floxed STOP codon inserted into 
Eflalpha locus. Expression induced by cre
(Buonamici et al., 2009) I
Notch3+/-
Exons coding for EGF repeats 8-12 deleted 
resulting in gene inactivation
(Krebs et al., 2003) III
DNMAML
Expresses a dominant negative, GFP 
tagged MAML protein. Transgene inserted 
into ROSA26 locus preceded by loxP 
flanked STOP codon. Inhibits canonical 
signaling by all Notch receptors upon cre 
expression (Figure 9)
(Tu et al., 2005) I, II
Prox1CreT2
Transgene expresses both Prox1 and 
CreERT2 where Prox1 is normally expressed
(Srinivasan et al., 2007) I, II
Prox1GFPcre
GFPCre cassette inserted into Prox1 locus, 
expresses a GFPCre fusion protein
(Srinivasan et al., 2010; 
Srinivasan and Oliver, 
2011)
I
TNR (Transgenic 
Notch Reporter)
Expresses GFP in response to canonical 
Notch signaling
(Duncan et al., 2005)/
JAX Labs
II
ROSAmT/mG
Express red fluorescence (mT) prior to Cre 
activity and GFP (mG) after
(Muzumdar et al., 2007)/
JAX Labs
II
ROSA:LacZfl/fl Express lacZ where Cre is expressed
(Soriano, 1999)/
JAX Labs
I, II
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Figure 9. Molecular mechanism of Notch inhibition by DNMAML. During Notch signaling, Mastermind-like 
is normally recruited to the transcription factor CSL together with the intracellular domain of Notch (ICN) 
and co-activators (Co-A) to transform the transcriptional repressor CSL into a transcriptional activator. The 
DNMAML protein only contains the N-terminal basic domain (BD) responsible for interaction with ICN and 
CSL but lacks transcriptional activation domains (TADs) required for Notch signaling. Thus, DNMAML inhibits 
canonical signaling all four Notch receptors. As CSL is able to bind to DNA in the presence of DNMAML 
this Notch inhibition does not interfere with transcriptional repression function of CSL. Adapted from 
McElhinny, et al. 2008. Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk 
among multiple signaling pathways. Oncogene; 27(38): 5138-47. Copyright license number 3620330062847.
Table 2. Antibodies
Antigen Source and Catalogue # Application Used in
α-tubulin Sigma-Aldrich, T6074 WB I, II
β-Galactocidase Abcam, Ab9361 IHC I
CD31 BD Pharmingen, 553370 IHC I, II
CD34 BD Pharmingen, 550537 IHC I
CD34-PE BD Pharmingen, 5550619 FACS I, II
Coup-TFII RnD Systems, PP-H7147-00 IHC I
Cx37 Alpha Diagnostics, CX37A11-A WB II
Dll4 RnD Systems, AF1389 IHC I
Endomucin Santa Cruz, sc-65495 IHC I
Ephrin B2 RnD Systems, AF496 IHC I
FN-EIIIA (clone FN-3E2) Sigma-Aldrich, F6140 IHC II
FN-EIIIA (IST9) Abcam, Ab6328 WB II
Fibronectin (total) Abcam, Ab23750 WB II
GFP Invitrogen, A-11122 IHC I
GFP Abcam, Ab6556 IHC II
Isolectin-B4 Vector Laboratories, B-1205 IHC IV
Integrin β1α9 Abcam, Ab27947 FACS II
Integrin-α9 RnD Systems, AF1057 IHC II
Jagged1 RnD Systems, AF599 IHC II
LYVE1 eBioscience, 14-0443 IHC I
LYVE1 RnD Systems, AF2089 IHC I
F gu e 9. Molecular mechanism of Notch in ibition by DNMAML. During Notch
signaling, Mastermind-like is normally recruited to the transcription factor CSL
together with the intracellular domain of Notch (ICN) and co-activators (Co-A) to
transform the transcriptional repressor CSL into a transcriptional activator. The
DNMAML protein only contains the N-te min basic domain (BD) responsible for
interaction with ICN and CSL but lacks transcriptional activation domains (TADs)
required for Notch signaling. Thus, DNMAML inhibits canonical signaling all four
Notch receptors. As CSL is able to bind to DNA in the presence of DNMAML this
Notch inhibition does not interfere with transcriptional repression function of CSL.
Adapted from McElhinny, et al. 2008. Mastermind-like transcriptional co-activators:
emerging roles in regulating cross talk among multiple signaling pathways.
Onco e; 27(38): 5138-47. Copyright licens number 3620330062847.
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Antigen Source and Catalogue # Application Used in
NG2 Millipore, AB5320 WB III
NG2 RnD Systems, MAB6689 IHC III
Notch1 (extracellular) RnD Systems, AF1057 IHC,WB I, II
Notch1 (intracellular) Abcam, Ab8387 IHC I
Notch2 Abcam, Ab8926 IHC I
Notch3 Abcam, Ab60087 IHC,WB I
Notch4 J.Kitajewski, RB2-2 IHC I
Nrp1 Abcam, Ab81321 IHC I
Nrp2 RnD Systems, AF2215 IHC I
Podoplanin Angiobio, 11-0033 IHC I
Prox1 Angiobio, 11-002 IHC I, II
Prox1 Millipore, AB5475 IHC I
αSMA-Cy3 Sigma, C6198 IHC III, IV
αSMA Sigma, A2547 IHC I
VEGFR-2 RnD Systems, AF644 IHC I
VEGFR-3 RnD Systems, AF743 IHC I, II
 
 
Table 3. Cell lines
Cell line Description Source or Reference Used in
HdLEC
Primary human dermal  
lymphatic endothelial cells
Isolated by Uh, 
M.K.
I, II
HdLEC-pccl-N1IC
HdLEC line expressing 
constitutively active intracellular 
domain of human Notch1
(Murtomaki et al., 
2013)
I
HdLEC-pccl-Hey1 HdLEC line expressing Hey1
(Murtomaki et al., 
2013)
I
HdLEC-pCCL.pccl-Hey2 HdLEC line expressing Hey2
(Murtomaki et al., 
2013)
I
HdLEC-pccl-GFP HdLEC line expressing GFP
(Murtomaki et al., 
2013)
I
HdMVEC
Primary human dermal 
microvascular endothelial cells
Lonza I
HUVEC
Primary human umbilical vein 
endothelial cells
Isolated by Uh, 
M.K.
I
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Table 4. Recombinant adenoviruses
Virus Description Source or Reference Used in
AdGFP Adenovirus that encodes GFP (Tung et al., 2009) II
AdLacZ Adenovirus that encodes β-galactosidase (Shawber et al., 2007) I, II
AdHey1 Adenovirus that encodes Hey1 (Murtomaki et al., 2013) II
AdHey2 Adenovirus that encodes Hey2 (Murtomaki et al., 2013) II
AdN1IC
Adenovirus that encodes constitutively active 
intracellular domain of human Notch1
(Shawber et al., 2007) I, II
AdN4/int3
Adenovirus that encodes a truncated form of Notch4 
consisting of the transmembrane and intracellular 
domain, and is constitutively active 
(Shawber et al., 2007) II
 
 
Table 5. Primers used in qRT-PCR
Amplicon Forward primer Reverse primer Used in
β-actin 5’ CGA GGC CCA GAG CAA GAG AG 3’ 5’ CTC GTA GAT GGG CAC AGT GTG 3’ I, II
Cx37 5’ GGT GGG TAA GAT CTG GCT GA 3’ 5’ GGC CGT GTT ACA CTC GAA AT 3’ II
Dll4 5’ CGG GTC ATC TGC AGT GAC AAC 3’ 5’ AGT TGA GAT CTT GGT CAC AAA ACA G 3’ I
FN-EIIIA+ 5’ TTG ATC GCC CTA AAG GAC TG 3’ 5’ ACC ATC AGG TGC AGG GAA TA 3’ II
FN-EIIIA- 5’ GGT AAC CAC CAT TCC TGC AC 3’ 5’ CCT GAT ACA ACC ACG GAT GA 3’ II
Hey1 5’ ACG AGA ATG GAA ACT TGA GTT C 3’ 5’ AAC TCC GAT AGT CCA TAG CAA G 3’ II
Hey2 5’ ATG AGC ATA GGA TTC CGA GAG TG 3’ 5’ GGC AGG AGG CAC TTC TGA AG 3’ II
Integrin – α9 5’ CGG AAT CAT GTC TCC AAC CT 3’ 5’ TCT CTG CAC CAC CAG ATG AG 3’ II
Jagged1 5’ GCT TGG ATC TGT TGC TTG GTG AC 3’ 5’ ACT TTC CAA GTC TCT GTT GTC CTG 3’ I
LYVE1 5’ TAG CTT TGA AAC TTG CAG CTA TG 3’ 5’ TCA ACA AAT GGT TCA GTT TCT GTA G 3’ I
Notch1 5’ CTC ACC TGG TGC AGA CCC AG 3’ 5’ GCA CCT GTA GCT GGT GGC TG 3’ I, II
Notch2 5’ CAG TGT GCC ACA GGT TTC ACT G 3’ 5’ GCA TAT ACA GCG GAA ACC ATT CAC 3’ I
Notch3 5’ CGC CTG AGA ATG ATC ACT GCT TC 3’ 5’ TCA CCC TTG GCC ATG TTC TTC 3’ I
Notch4 5’ GGT GAC ACC CCT GAT GTC AG 3’ 5’ AGC CTG GCA GCC AGC ATC 3’ I, II
Podoplanin 5’ CCC AGG AGA GCA ACA ACT CAA C 3’ 5’ CTC GAT GCG AAT GCC TGT TAC 3’ I
Prox1 5’ ACG TAA AGT TCA ACA GAT GCA TTA C 3’ 5’ CCA GCT TGC AGA TGA CCT TG 3’ I
VEGFR-2 5’ GGA CTG GCT TTG GCC CAA T 3’ 5’ CTT GCT GTC CCA GGA AAT TCT G 3’ I
VEGFR-3 5’ GAG ACC TGG CTG CTC GGA AC 3’ 5’ TCA GCA TGA TGC GGC GTA TG 3’ I
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Isolation of HUVECs and HdLECs/cell culture (I, II)
Human dermal microvascular endothelial cells (HdMVEC, Lonza) were maintained 
in EGM-2 MV medium. Human umbilical vein endothelial cells (HUVEC) were 
isolated from neonate umbilical veins by collagenase digestion as previously 
described (Jaffe et al., 1973) and maintained in EGM-2 Endothelial Cell Growth 
Medium (CC-3162, Lonza). 
Human dermal lymphatic endothelial cells (HdLEC) were isolated from 
neonate foreskins. Foreskins were digested in DMEM low glucose medium (Gibco) 
supplemented with Ca2+/Mg2+, 2% fetal bovine serum, 1X pen-strep (100U penicillin 
and 100U streptomycin, Invitrogen) and 1mg/ml collagenase A (Roche) for 30min 
at 37°C in a rotating incubator. Subsequently, an equal volume of “Buffer A” (PBS 
supplemented with 5mg/ml bovine serum albumin and 0.6% Acid citrate dextrose 
solution) was added and tissue was homogenized with a cell scraper to release 
cells. The procedure was repeated three times. The solution containing the cells 
was filtered through a 100µm cell strainer, centrifuged at 1500rpm for 5min at 4°C 
and resuspended in Buffer A. Magnetic Dynabead system (Invitrogen) was used to 
separate CD31+ cells from the solution according to the manufacturer’s instructions. 
The cells were expanded and first positively sorted for podoplanin (Angiobio) and 
then negatively sorted for CD34 (Pharmingen) to remove any remaining blood 
endothelial cells. Resulting CD31+; podoplanin+; CD34-HdLECs were maintained 
on fibronectin-coated plates in EGM-2MV BulletKit (Lonza) with 10ng/ml VEGF-C 
(RnD) and used before passage 7.
Adenoviral infection of cells (I, II)
1x106 HdLECs were infected in suspension at a multiplicity of infection (MOI) of 20 
in low serum (2%) media for 1h at 37°C gently rotating the plates manually every 
15min (Shawber et al., 2007). Cells were subsequently plated in growth medium 
and RNA and protein isolated 48h after infection. 1x106-3x106 of early passage 
HdMVECs were infected in suspension at 25 pfu/cell for 1h at 37°C, grown in growth 
medium and RNA and protein isolated 48h after adenoviral infection. Transgene 
expression was validated by Western blot analysis and qRT-PCR.
Generation of stable HdLEC cell lines by lentiviral transfection (I)
For Notch activation studies in HdLECs, 293T cells were transfected with 10µg of 
lentiviral vectors pccl-GFP, pccl-N1IC, pccl-Hey1 or pccl-Hey2. 48h after transfection 
the supernatant produced by the 293T cells containing the lentiviral particles was 
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collected (Tung et al., 2009). It was then passed through a 0.45µm filter and used 
to replace the normal growth medium of target cells. RNA and protein were isolated 
48h after infection. Transgene expression or knockdown was validated by western 
blot analysis and/or qRT-PCR.
Activation of endogenous Notch signaling in HdLECs with EDTA (I)
Confluent plates of HdLECs were first treated with 200nM of compound E 
overnight at 37°C to quench endogenous Notch signaling and get an easily detectable 
induction. The following day, compound E was removed and cells washed with PBS. 
Subsequently, endogenous Notch signaling was activated in HdLECs by treating 
with 10mM EDTA for 15min at 37°C. Medium was then replaced with normal 
HdLEC growth medium and RNA isolated at multiple time-points. DMSO was 
used as a control.
Gene expression analysis by qRT-PCR (I, II)
RNA isolation from cultured cells was performed using the RNeasy Mini Kit 
according to the manufacturer’s instructions (Qiagen). Isolated RNA was treated 
with DNase1 for 30min prior to using it as a template for reverse-transcription 
PCR. RT-PCR was performed with VersoTM Reverse Transcriptase kit according 
to the manufacturer’s instructions (Thermo Fisher). Quantitative Real-Time PCR 
(qRT-PCR) was performed in triplicate for each sample using Sybr Green Master 
Mix (ABI) or ABsoluteTM Blue qPCR SYBR Green ROX Mix (Thermo Fisher) and 
the Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems). Primers 
used are listed in Table 5. Specific standards for each gene of interest were created by 
cloning PCR amplicons into pDrive. β-actin (I, II) qRT-PCR was used to normalize 
samples. Data was analyzed using Microsoft Excel.
Protein expression analysis by Western blot (I, II)
Cell lysates were isolated from cultured cells using cold TENT lysis buffer (50mM 
Tris pH8.0, 2mM EDTA, 150mM NaCl, 1% Triton X-100) containing HaltTM Protease 
Inhibitor Cocktail (Pierce). 20µg-40µg of total cell lysates were separated by SDS-
PAGE and transferred onto nitrocellulose membranes. Membranes were blocked 
for 30min in PBS with 0.1% Tween, 2% milk and 2% BSA at RT on a rotator, 
and subsequently incubated overnight at 4°C with primary antibodies diluted in 
blocking buffer (Table 2). The next day, membranes were incubated for 30min at 
50
Materials and methods
room temperature with the appropriate HRP-conjugated secondary antibodies in 
blocking buffer at 1:5000. Proteins were detected using Amersham ECL Western 
Blotting Detection Reagents (GE Healthcare Life Sciences). 
Flow cytometry (II)
Adenovirally infected HdLECs were detached by scraping, blocked in PCN buffer 
containing 5% FBS and incubated with anti-α9β1 antibody (Abcam, Table 2) diluted 
in PCN buffer for 30min at 4°C. Cells were washed three times in PCN buffer followed 
by incubation with anti-rabbit-APC diluted in PCN buffer at 1:200 for 20min at 
4°C. After three washes with PCN buffer cells were passed through filter tops into 
polystyrene tubes. Ten thousand cells were analyzed with BD FACSCaliburTM flow 
cytometer and CellQuestPro acquisition software.
Transgenic mouse models (I, II)
All procedures were performed according to approved protocols and following 
guidelines established by the Columbia University Institutional Animal Care and 
Use Committee. In order to activate or inactivate gene expression in mouse embryos, 
cre-carrying driver mice were bred to mice carrying transgenes or floxed target 
genes. Recombination was induced by tamoxifen delivery either via oral gavage 
or intraperitoneal injection to the pregnant females. For early embryonic studies, 
5mg/40g or 7mg/40g tamoxifen was administered at E9.75, E10.5, E13.5 or E14.5 
(I). For later studies, 10mg/40g was administered at E13.5 or E15.5 (II). Tamoxifen 
was dissolved in corn oil. Embryonic time-points were estimated from the day when 
vaginal plug was first observed and the day when plug was observed was considered 
embryonic day 0.5. As controls, single transgenic or wild-type littermates were used. 
None of the single transgenic mice displayed any obvious phenotype. Two to six 
litters were analyzed for each time-point.
Notch inhibition using Notch1 decoys and analysis of  
retinal angiogenesis (IV)
P2 C57BL/6 mouse pups were injected subcutaneously with 2.5 x 108 focus forming 
units (ffu) of adenoviruses encoding different Notch1 decoys or Fc as a control. A 
total volume of 50 µl per pup was injected. Eye balls were isolated at P5 and retinal 
vasculature and mural cells visualized via fluorescent staining as described below. 
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Blood sample was collected from each pup at the time of sacrifice and Western blot 
analysis performed to verify decoy protein expression.
Immunohistochemistry of retinas (III, IV)
For analysis of angiogenic sprouting and mural cell recruitment P5 mouse pups 
were sacrificed and eyes collected. The eyes were fixed in 4% paraformaldehyde 
(PFA) for 2h at 4°C. Retinas were dissected out, rinsed with wash buffer (0.1% 
Triton-X-100 in PBS) and incubated in blocking solution (0.5% Triton-X-100- 
1% BSA) two hours at room temperature or overnight at 4°C. Subsequently, the 
retinas were incubated overnight at 4°C in blocking solution containing biotinylated 
Isolectin-B4 (1:50 dilution, Vector Laboratories) and additional primary antibodies 
(anti-αSMA, anti-NG2, anti-CD31). The following day retinas were washed several 
times with wash buffer and then incubated with Alexa Fluor-488, -594 or -647 
conjugated secondary antibodies (1:500 dilution, Invitrogen) in blocking solution 
overnight at 4°C or for 2 hours at room temperature. Retinas were washed several 
times with wash buffer, post-fixed with 4% PFA for 15 minutes at room temperature 
and washed several times with PBS. Finally, retinas were mounted on slides with 
mounting media containing 90% glycerol in 0.1M Tris pH8 and 1µg/ml of Hoechst 
nuclear stain (Sigma).
β-galactosidase staining (II)
Dorsal skins of E18.5 embryos were isolated and fixed in 0.2% glutaraldehyde, 2mM 
MgCl2 and 5mM EGTA in 100mM phosphate buffer for 30min at room temperature 
followed by several washes with wash buffer (2mM MgCl2, 0.02% NP-40 and 0.01% 
deoxycholate in 100mM phosphate buffer). Samples were stained overnight at 37°C 
with solution containing 1mg/ml X-gal, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 2mM 
MgCl2, 0.02% NP-40 and 0.01% deoxycholate in 100mM phosphate buffer. After 
several washes with wash buffer, samples were post-fixed with 4% PFA for 15min 
at RT and then washed several times with PBS before mounting on glass slides 
with 85% glycerol. 
Immunohistochemistry of mesenteries (I, II)
Embryonic intestines were collected preserving the mesenteries intact at E16.5, 
E17.5 and E18.5. Samples were pinned down on silicon-coated plates with insect 
pins (Fisher Scientific), fixed with 4% PFA 2h, washed several times with wash 
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buffer (0.3% Triton-X-100 in PBS) at 4°C and blocked with donkey blocking 
solution (5% donkey serum, 0.2% BSA and 0.5% Triton-X-100 in PBS) for 2h at 
room temperature or overnight at 4°C. Samples were then incubated with primary 
antibodies (Table 2) diluted in blocking solution overnight at 4°C, washed several 
times with wash buffer and again incubated overnight with Alexa Fluor 488, 594 
or 647 secondary antibodies (Invitrogen) diluted at 1:500 in 0.5% BSA in 0.5% 
Triton-X-100. Following several washes with wash buffer, samples were post-fixed 
with 4% PFA for 5min at room temperature and mounted on glass slides with 
mounting medium containing containing 90% glycerol in 0.1M Tris pH8 and 1µg/
ml of Hoechst nuclear stain (Sigma). Mouse-on-mouse (MOM) detection kit (Vector 
laboratories) was used with mouse monoclonal antibodies. 
Immunohistochemistry of cryo- and paraffin sections (I)
For cryosectioning, E9.75, E10.5, E13.5 E14.5 and E16.5 embryos were collected, 
fixed with 4% PFA overnight at 4°C, immersed in 30% sucrose overnight at 4°C and 
embedded in OCT. 5µm and 30µm sections were cut, dried, acetone-fixed, blocked 
1h at room temperature (3% BSA and 2% appropriate serum in PBS) and incubated 
with primary antibodies (Table 2) diluted in blocking solution. The following day 
sections were washed with PBS, incubated with Alexa Fluor secondary antibodies 
(Invitrogen) diluted at 1:1000 in blocking solution for 1h at room temperature and 
mounted with Vectashield containing DAPI (Vectorlabs, H-1200).
For paraffin sectioning, embryos were isolated at E14.5, fixed overnight at 
4°C in 4% PFA, dehydrated and embedded in paraffin. 5µm sections were cut, 
deparaffinazed and rehydrated followed by sodium citrate antigen retrieval. 
Sections were blocked, incubated in appropriate primary antibodies, washed and 
primary antibodies detected with appropriate biotinylated antibodies (Vector 
Laboratories) and visualized with either Vectastain Standard ABC Elite Kit (Vector 
Labs) or streptavidin-conjugated Alexa Fluor 488 or 594 secondary antibodies 
(Invitrogen). Mouse-on-mouse (MOM) detection kit (Vector labs) was used with 
mouse monoclonal antibodies. Hematoxylin counterstain was performed on slides 
stained colorimetrically.
Image acquisition (I, II, III, IV)
Images of fluorescently labeled, wholemount mesenteries and retinas were acquired 
with a laser scanning confocal Zeiss LSM 510 Meta microscope and LSM software 
and a Nikon A1R confocal laser scanning microscope and NIS Elements software. 
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Cryosections and paraffin-embedded sections imaged using a Nikon SMZ-U 
Zoom 1:10 microscope and Nikon 4500 digital camera, Nikon ECLIPSE E800 
microscope, Nikon DXM 1200 digital camera and Image ProPlus software or Nikon 
A1R confocal laser scanning microscope and NIS Elements software. ImageJ and 
Adobe Photoshop were used for image processing.
Quantification (I, II) 
ImageJ was used for all quantification. In embryo cross sections and wholemounts, 
number of Prox1+ cells was determined by manually counting Prox1+ cells. 
Threshold for Prox1+ was set for control samples first and applied to all slides 
analyzed. In cross sections, number of Prox1+ cells within the CV and lymph sacs 
(LS) was normalized to CV and LS circumference, respectively. Number of Prox1+ 
cells emerging from the CV was normalized to area analyzed. LYVE1+ LS and vessel 
luminal area were normalized to area quantified. In embryo wholemounts, the 
number of Prox1+ cells within the CV and emerging from the CV was normalized 
to area analyzed. 
In the mesenteries, Prox1high cells were manually counted and normalized to µm 
duct length to quantify number of Prox1high cells relative to duct length. Threshold 
for Prox1high cell was determined for control ducts first and the applied to all images 
analyzed. The percentage of Prox1high cells located in valve clusters was determined 
by manually counting Prox1high cells in and outside of clusters. A cluster was defined 
as a group of Prox1high cells in which nuclei appeared to be physically in close contact 
with each other. Percentage of Prox1high cells within the Prox1high clusters reorienting 
at least 45° to the duct wall was also determined by manually counting the cells that 
had reoriented and the cells that had not reoriented. Prox1/integrin-α9/FN-EIIIA 
triple-positive valves were counted in 10x pictures and the number normalized to 
the amount of ducts in each picture. Integrin-α9 and FN-EIIIA-positive signal at 
the sites of valve formation was measured by first setting the threshold for control 
valves and applying it to all images. Valve sites were defined as clusters of Prox1high 
cells. Integrin-α9 and FN-EIIIA signal was normalized to Prox1high signal at valve 
formation sites.
Statistical analysis (I, II)
Statistical significance was determined using two-tailed student’s t-test and p-values 
less than 0.05 were considered significant. Error margins indicate either standard 
error of mean or standard deviation, as indicated. All data represents three or more 
independent experiments unless stated otherwise.
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1. Notch functions as a negative regulator of lymphatic 
endothelial cell differentiation in the venous endothelium (I)
Previous studies have established that lymphatic endothelial cells differentiate from 
the venous endothelium in the cardinal vein and that Prox1 is crucial for the process 
(Srinivasan et al., 2007). However, Prox1 is only expressed in a subset of endothelial 
cells in the CV: the ECs that do not express Prox1 maintain their venous identity. 
Although it has been shown that Sox18 and Coup-TFII induce Prox1 expression 
and are required for lymphatic differentiation (Francois et al., 2008; Lee et al., 
2009; Srinivasan et al., 2010), it is not known whether another signaling pathway 
is required to further suppress lymphatic endothelial fate and/or promote venous 
endothelial identity in the cells that do not adopt the lymphatic fate. Notch signaling 
mediates cell fate decisions during development and importantly, is required for 
arterio-venous specification during remodeling of the primary vascular plexus 
(Duarte et al., 2004; Kim et al., 2008; Lawson et al., 2001; Trindade et al., 2008). 
Therefore, we hypothesized that Notch mediates the decision between venous and 
lymphatic fate in the CV during lymphatic specification. 
We found that Notch1 and Jagged1 were expressed in the ECs in the CV at 
E9.75 and E10.5, at the time when lymphatic specification occurs. Their expression 
patterns were punctate and overall weaker than in the adjacent aortic endothelium. 
Interestingly, we often observed stronger and more continuous staining on the 
ventral side and weaker and more punctate on the dorsal side of the CV. We also 
detected Notch activity in some of the Notch1 expressing cells in the CV at E9.75 
using a transgenic Notch reporter (TNR) mouse, which expresses GFP in response 
to CSL-dependent Notch signaling. Again, the Notch activity detected in the CV 
was weaker and more discontinuous than in the aorta. Co-staining for Notch1 and 
Prox1 revealed that the Prox1+ LEC progenitors often resided on the dorsal side 
that had less Notch1 expression and that Prox1+ LECs migrating out of the CV 
had no or very low Notch1 expression. On the other hand, the Prox1+ cells still 
residing in the CV were sometimes Notch1+ and the cells expressing high levels of 
Notch1 were Prox1 negative. The expression patterns suggest that fully differentiated 
LECs have little or no Notch1 while the ECs maintaining their venous identity also 
maintain Notch1 expression. Both Notch1 and Jagged1 expression levels in the CV 
at E9.75 and E10.5 were weaker than what was observed in the adjacent aortic 
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endothelium and the same Notch1 pattern was observed in embryonic mesenteries 
at E16.5 and E17.5. It has been shown in T-cell development that different levels 
of Notch signaling can activate different target genes (Liu et al., 2010a). Thus, it 
is possible that different levels of Notch1 observed translate into different gene 
expression profiles in endothelial cells. Furthermore, Notch function may not be 
solely limited to arterial endothelial fate as has been previously suggested. Indeed, 
we observed that ectopic Notch activation in Prox1+ LEC progenitor cells did not 
result in arterial marker expression, suggesting that Notch mediated arterialization 
in ECs might be restricted to a certain developmental window. Alternatively, once 
LECs express Prox1 they are no longer susceptible to Notch-induced arterial fate.
To further study the role of Notch in lymphatic specification, we both inactivated 
and activated Notch signaling in LEC progenitors. We utilized a tamoxifen 
responsive, lymphatic endothelial specific Prox1CreERT2 mouse line that drives 
cre-expression in Prox1+ cells without disrupting Prox1 expression from the locus 
(Srinivasan et al., 2007) in combination with a floxed Notch1 allele (N1fl/+)(Yang 
et al., 2004). To disrupt Notch1 signaling we crossed Prox1CreERT2;N1fl/+ males to 
N1fl/+ females. In order to inhibit canonical signaling through all four Notch proteins, 
we crossed Prox1CreERT2 driver mice to mice carrying a transgene encoding a 
dominant-negative form of MAML (DNMAML) (Tu et al., 2005).  DNMAML 
binds to N1IC-CSL complex but is unable to recruit co-activators thus inhibiting 
canonical signaling through all four receptors (Figure 9). To ectopically activate 
Notch signaling, we crossed Prox1CreERT2 drivers to mice carrying a transgene 
encoding constitutively active Notch1 intracellular domain (N1IC) (Buonamici et 
al., 2009). Loss of Notch1 or Notch signaling through DNMAML expression in LEC 
progenitor cells at E9.75, the time of lymphatic specification, resulted in increased 
numbers of ECs committing to the lymphatic lineage. We observed an increase in 
the number of Prox1+ cells remaining in and emerging from the CVs of the mutant 
embryos, as well as enlarged lymphatic sacs and vessels at E14.5. We occasionally 
observed connections between podoplanin positive vessels and the CV indicating a 
defect in blood and lymphatic separation. These data show that Notch suppresses 
Prox1 expression in the CV to ensure that only a subset of ECs in the CV adopts the 
lymphatic fate. We next included Prox1GFPCre/+ mice which carry a GFPcre expression 
cassette in one Prox1 allele, resulting in Prox1 haploinsufficiency and embryonic 
lethality (Srinivasan et al., 2010; Srinivasan and Oliver, 2011). We crossed N1fl/fl 
mice with Prox1GFPCre/+ mice to determine whether loss of one copy of Notch1 would 
rescue the lethality caused by Prox1 haploinsufficiency as could be predicted since we 
hypothesized that Notch1 suppresses Prox1. Indeed, we observed predicted numbers 
of Prox1GFPCre/+;N1fl/fl pups and an increase in Prox1+ LEC progenitors compared 
to Prox1GFPCre/+pups indicating that loss of one copy of Notch1 in the lymphatic 
progenitors was able to rescue lethality caused by Prox1 haploinsufficiency.
Ectopic activation of Notch1 in Prox1+ progenitors at E9.75 or at E10.5 lead to 
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edema, blood filled lymphatic vessels and embryonic lethality by E15.5. Upon closer 
examination of Prox1CreERT2;N1IC embryos, we observed poorly formed, blood 
filled lymph sac like structures that had reduced podoplanin, LYVE1 and VEGFR-3 
and spotty Prox1 expression at E14.5. The number of Prox1+ ECs detected in the 
mutant embryos was significantly reduced compared to controls, suggesting that 
Notch1 suppresses Prox1 expression in vivo. Using in vitro analysis, we showed that 
ectopic activation of Notch1 in cultured HdLECs via adenoviral infection resulted 
in suppression of Prox1 transcripts and protein. VEGF-C/VEGFR-3 signaling is 
the main pathway mediating LEC migration ((Karkkainen et al., 2004; Zhang 
et al., 2010), thus it was surprising to see that LEC progenitors expressing no 
detectable levels of VEGFR-3 still emerged from the CV in Prox1CreERT2;N1IC 
embryos. VEGFR-3 co-receptor Nrp2 has been shown to promote VEGF-C-guided 
LEC migration in vitro and recently, a Nrp2high/LYVE1low population of LECs has 
been identified that migrate directly out of the CV and form peripheral lymphatics 
(François et al., 2011; Karkkainen et al., 2004; Xu et al., 2010). As Nrp2 expression 
was unchanged in Prox1CreERT2;N1IC embryos it is possible that Nrp2 is able to 
mediate LEC migration, even with dramatically reduced VEGFR-3 levels. It is not 
known whether the Nrp2high/LYVE1low cells also express VEGFR-3 or are able to 
migrate without VEGFR-3. Our in vitro data showed that Notch1 transiently induces 
VEGFR-3 in HdLECs followed by repression of VEGFR-3, likely mediated by the 
later Notch1 induction of the transcriptional repressors Hey1/Hey2. An alternative 
explanation to the migration seen in Prox1CreERT2;N1IC embryos is that the 
transient VEGFR-3 induction by N1IC was sufficient to promote LEC progenitor 
migration out of the CV. Alternatively, VEGFR-3 levels below antibody detection 
are sufficient for LEC progenitor cell migration from the CV.
Sox18 and Coup-TFII are expressed in the CV and induce Prox1 expression in 
LEC progenitors between E9.75 and E13.5 (Francois et al., 2008; Lee et al., 2009; 
Srinivasan et al., 2010). We explored the possibility that Notch might regulate 
Prox1 via regulation of one of these transcription factors. Using cultured HdLECs, 
we demonstrated that Notch did not regulate Sox18 expression in vitro. However, 
the effect of Notch on Sox18 expression in vivo remains to be determined. As data 
from blood vasculature suggest that Notch downregulates Coup-TFII (You et al., 
2005), we analyzed Coup-TFII expression pattern in wild-type embryos at the time 
of lymphatic specification, E10.5, and Prox1CreERT2;N1IC embryos at E12.5 and 
E13.5 in which Notch activation was induced at E10.5. In wild-type embryos at 
E10.5, Notch activity and Coup-TFII expression patterns in the CV did not overlap 
but were observed in neighboring cells suggesting that Notch indeed suppresses 
Coup-TFII in the CV. Following tamoxifen administration and Notch activation at 
E10.5, Prox1CreERT2;N1IC embryos revealed a significant reduction of Coup-TFII 
expression both in venous endothelium and presumptive lymphatic endothelium 
at E12.5 or E13.5. 
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It has been shown that Coup-TFII regulates Prox1 expression within a 
developmental window between E9.75 and E13.5 (Srinivasan et al., 2010). In order 
to determine if Notch regulation of Prox1 was limited to the same developmental 
window, we administered tamoxifen at E13.5 or E14.5 and analyzed control and 
Prox1CreERT2;N1IC embryos at E16.5 or E18.5. Tamoxifen administration at E13.5 
resulted in a mild lymphatic phenotype in about 40% of the Prox1CreERT2;N1IC 
embryos. Administration at E14.5 resulted in Prox1CreERT2;N1IC embryos that 
were indistinguishable from control embryos and had similar levels of Prox1 and 
podoplanin expression as controls. Therefore, we found that Notch regulates Prox1 
between E9.75 and E13.5 and not beyond. As this is the same developmental window 
for Coup-TFII regulation of Prox1, it is likely that Notch inhibits Prox1 through 
suppression of Coup-TFII.
Together these data suggest that Notch1/Jag1 signaling in a subset of cardinal 
vein ECs during lymphatic specification inhibits Prox1 signaling via suppression of 
Coup-TFII. Notch-mediated inhibition of Prox1 leads to suppression of lymphatic 
differentiation in these ECs and maintenance of venous identity, while lack of Notch 
signaling in the adjacent cells results in Coup-TFII expression, Prox1 induction and 
adoption of lymphatic fate. Therefore, Notch signaling restricts the amount of ECs 
that differentiate into LECs, thus ensuring proper lymphatic development. Recent 
work has showed that Notch functions in postnatal lymphatic sprouting in both 
physiological and pathological settings (Niessen et al., 2011; Zheng et al., 2011). As 
we discovered that Notch no longer suppresses Prox1 after E13.5, our findings are 
not in conflict with Notch functioning in Prox1+ lymphatic endothelium later in 
development, such as sprouting lymphangiogenesis.
2. Notch signaling functions in lymphatic valve formation (II)
During lymphatic valve morphogenesis a subset of LECs in the lymphatic duct wall 
undergoes changes in gene expression, cytoskeletal rearrangements, reorients and 
differentiates into a distinct population of cells referred to as valve-forming LECs. 
These valve-forming LECs secrete a specialized valve ECM, assemble the leaflet 
core and form valve leaflets (Bazigou et al., 2009; Sabine et al., 2012). Prox1, Foxc2, 
integrin-α9, fibronectin splice variant EIIIA (FN-EIIIA) and gap junction protein 
37 (connexin37, Cx37) are highly expressed in valve-forming LECs and all, other 
than Prox1, have been shown to be required for normal lymphatic valve formation 
(Bazigou et al., 2009; Kanady et al., 2011; Norrmen et al., 2009; Petrova et al., 2004; 
Sabine et al., 2012). Prox1 expression is higher in valve-LECs (Prox1high) than LECs 
in the duct wall (Prox1low) and Prox1 is necessary in a dosage-dependent manner 
for lymphovenous valve formation (Srinivasan and Oliver, 2011), suggesting that 
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high Prox1 levels seen in valve-forming LECs are similarly required for lymphatic 
valve formation. Although previous studies have established the importance of these 
valve regulators for valve morphogenesis, it has not been known what triggers 
their expression and how a subset of LECs adopts the valve-LEC fate while the 
other LECs remain in the duct walls. As Notch mediates binary cell fate decisions 
in various developmental settings, including during lymphatic specification, we 
explored the hypothesis that Notch functions in the differentiation events associated 
with lymphatic valve formation.
We found that Notch1 was expressed in the developing mesenteric lymphatic 
vessels and valves. At E16.5 Notch1 was uniformly expressed throughout the 
mesenteric lymphatics. At E17.5, highest Notch1 expression was seen in, and 
immediately around, the putative valves. By E18.5, Notch1 expression was enriched 
in lymphatic valve-LECs and only weak expression was seen elsewhere in the 
duct. Using a transgenic Notch reporter mouse that expresses GFP in response to 
canonical Notch signaling we observed Notch signaling activity in valve-forming 
LECs at E17.5 and E18.5. At both time points, Notch activity was also seen outside 
the putative valves, however, the strongest signal was seen in reoriented valve-
forming LECs. We sought to determine which ligand induces signaling through 
Notch1 during valve formation. Despite our efforts to stain for Jagged1, Dll1 and 
Dll4, we were unable to obtain results that would identify a Notch ligand that might 
function in lymphatic valve formation (unpublished data by Murtomaki A., data 
not shown). The enrichment of Notch1 and Notch activity to lymphatic valves as 
valve morphogenesis proceeds suggested that Notch functions in valve formation.
To assess Notch1 function in lymphatic valve formation, we crossed male mice 
carrying the lymphatic endothelium-specific Prox1CreERT2 driver (Srinivasan et 
al., 2007) and one copy of a floxed allele of Notch1 (N1fl/+) (Yang et al., 2004) 
to N1fl/+ females. We administered tamoxifen at E15.5, the time when valve 
morphogenesis begins, and analyzed valve morphology and marker expression 
in mesenteric lymphatics at E18.5, by this time, most valves are mature. At E18.5, 
Prox1CreERT2;N1fl/fl (LOF) embryos were externally indistinguishable from control 
littermates. Upon examining the mesenteric lymphatics, we observed an increase 
in the amount Prox1high cells in LOF mesenteries. Occasionally, large expansions of 
Prox1high cells were seen in LOF mesenteries instead of typical, well-defined valve 
clusters. 
In control mesenteries, valve-forming Prox1high LECs clustered and reoriented 
at least 45° perpendicularly to the duct wall. However, even when Prox1high LECs 
clustered in LOF mesenteries, they often failed to reorient. We observed a significant 
reduction in the number of LECs reorienting at the putative valve sites. The valves 
that were seen in the LOF mesenteries often displayed abnormal morphology 
and poorly organized leaflets. As valve leaflet organization requires integrin-α9 
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and FN-EIIIA (Bazigou et al., 2009), we analyzed the expression pattern of these 
valve markers. We observed reduced integrin-α9 expression in LOF mesenteries 
compared to control mesenteries. The overall amount of lymphatic valves defined 
as clusters of Prox1high cells, albeit poorly organized, was similar in both LOF and 
control mesenteries, suggesting valve initiation still occurs. 
As we did not observe a complete loss of valves in Prox1CreERT2;N1fl/fl embryos, 
we hypothesized that another Notch protein might be expressed in developing valves 
and compensate for the loss of Notch1. To explore this we inhibited canonical Notch 
signaling through all four receptors in the lymphatic endothelium by crossing the 
Prox1CreERT2 drivers to mice carrying a transgene expressing a dominant-negative 
form of MAML (DNMAML) (Tu et al., 2005). We administered tamoxifen at E13.5 
or E15.5 and analyzed mesenteries at E18.5. The DNMAMLfl/+ transgene expresses 
GFP upon recombination and therefore the recombination efficiency was assessed 
by GFP staining. GFP signal was only observed in the lymphatic endothelium of 
Prox1CreERT2;DNMAMLfl/+ (DNMAML) embryos. Prox1CreERT2;DNMAMLfl/+ 
embryos displayed a more severe phenotype than Notch1 LOF embryos. The 
expected Prox1 expression pattern with valve-LECs being Prox1high and duct LECs 
Prox1low was seen in control mesenteries. However, the pattern was disrupted in 
Prox1CreERT2;DNMAMLfl/+ mesenteries with both E13.5 and E15.5 tamoxifen 
administration with significantly less Prox1high LECs located in clusters. Furthermore, 
LECs observed in clusters at putative valve sites displayed abnormally rounded 
nuclei instead of the elongated nuclei seen in control valve-LEC clusters. The overall 
number of Prox1/integrin-α9/FN-EIIIA triple-positive valves was also reduced in 
Prox1CreERT2;DNMAMLfl/+ mesenteries compared to control mesenteries. Even 
when putative valves were observed, they were morphologically abnormal displaying 
poorly formed leaflets and only expressing one of the valve markers analyzed, 
integrin-α9 or FN-EIIIA. Indeed, we observed significant reduction in FN-EIIIA 
expression by Prox1+ valve-LECs in the Prox1CreERT2;DNMAMLfl/+ mesenteries 
compared to control mesenteries. We were not able to reach significance for loss 
of integrin-α9 largely due to the small number of valves that expressed integrin-α9 
in the Prox1CreERT2;DNMAMLfl/+ embryos.
As lymphatic valve proteins integrin-α9 and FN-EIIIA were reduced in Notch1 
LOF and Prox1CreERT2;DNMAMLfl/+ mesenteries, respectively, we sought to 
determine if Notch regulates their expression. We adenovirally infected cultured 
HdLECs to express constitutively active forms of Notch1 (N1IC) or Notch4 (N4/int3) 
intracellular domains, the latter included to determine whether Notch4 functions 
in valve morphogenesis in addition to Notch1. We included Cx37, calcineurin 
regulatory subunit Cnb1, and Foxc2 in our target gene analysis as they are expressed 
in valves and required for valve formation (Kanady et al., 2011; Norrmen et al., 
2009; Petrova et al., 2004). Both N1IC and N4/int3 induced integrin-α9 and FN-
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EIIIA transcripts, although the effect of N4/int3 on FN-EIIIA transcript levels was 
less robust. Only N1IC induced integrin-α9 surface expression while both N1IC and 
N4/int3 induced FN-EIIIA protein levels. The lack of N4/int3-induced integrin-α9 
surface expression might be due to its lower signaling activity compared N1IC, 
which is seen in all experiments as a lower induction of Notch targets, Hey1 and 
Hey2. The transcriptional repressors Hey1 and Hey2 did not affect integrin-α9 
transcript levels. Both N1IC and N4/int3 strongly induced Cx37 transcript and 
protein expression. N1IC or N4/int3 induced Foxc2 transcripts slightly (1.5-fold) 
while neither affected the transcript levels of Cnb1.
Our data demonstrate that Notch functions in multiple steps of lymphatic valve 
morphogenesis. Differentiation and clustering of Prox1high cells at the putative valve 
sites is the first stage of valve formation. We observed increased numbers of Prox1high 
cells and lack of clustering in LOF and Prox1CreERT2;DNMAMLfl/+ mesenteries, 
respectively, suggesting that Notch might function to restrict the amount of LECs that 
become valve-forming LECs and/or promote clustering. In this model, lymphatic 
ducts must generate distinct Prox1high cells in order to initiate valve formation; in the 
absence of Notch activity developing lymphatic ducts have dysregulated Prox1 levels, 
and valve formation is impaired. As these processes are still poorly understood, 
the exact mechanism for Notch function during valve initiation stage remains to 
be determined. 
After the first stage, valve-forming LECs form a ring-like structure and reorient. 
We observed defects in Prox1high cell reorientation within the putative valve sites in 
LOF mesenteries. Cx37 functions in gap-junction formation and, valve-LECs in Cx37-
/- mice fail to reorganize into a ring-like structure and reorient (Kanady et al., 2011; 
Sabine et al., 2012). We showed that Notch strongly induced Cx37 transcript and 
protein levels in cultured HdLECs. Therefore, it is possible that the reorientation defect 
seen in LOF valves results from loss of Cx37 and impaired cell-cell communication. 
Cx37 expression levels in Notch1 LOF and Prox1CreERT2;DNMAMLfl/+ mesenteries 
still need to be determined in order to further elucidate the issue. 
Upon reorientation valve-LECs penetrate into the vessel lumen, elongate, 
assemble the ECM core and leaflets. Integrin-α9 and FN-EIIIA are required for valve 
ECM core assembly and leaflet elongation and the loss of either results in abnormal, 
shortened valve leaflets and disorganized valve matrix core (Bazigou et al., 2009; 
Sabine et al., 2012). We observed poorly formed and disorganized valve leaflets 
as well as reduction in integrin-α9 and FN-EIIIA expression in Notch1 LOF and 
Prox1CreERT2;DNMAMLfl/+ mesenteries. The fact that valve formation was severely 
impaired in Notch mutant mesenteries, leading to a significant reduction in number 
of Prox1/integrin-α9/FN-EIIIA-triple positive valves in Prox1CreERT2;DNMAMLfl/+ 
mesenteries, suggests that Notch controls several aspects of valve formation.
To conclude, we propose that Notch regulates several aspects of valve 
morphogenesis. Disruption of Prox1high/Prox1low pattern and clustering defects 
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demonstrate that Notch functions during the initial phases to separate valve-
LECs from the ductal LECs and promote their clustering at the putative valve 
sites. Furthermore, our data suggest that Notch promotes reorientation possibly 
through regulation of Cx37 in valve-LECs and subsequent leaflet formation through 
regulation of integrin-α9 and FN-EIIIA. We observed strong Notch1 expression 
and activity in mesenteric valves at E18.5, when valve morphogenesis is mostly 
completed, suggesting a potential role in valve maintenance. Whether Notch is 
required for maintenance of mature valves, remains to be determined. The more 
severe phenotype observed in Prox1CreERT2;DNMAMLfl/+ mice compared to Notch1 
LOF mice indicated that another Notch receptor functions in valve formation. Our 
in vitro data suggest that Notch4 is a likely candidate, however, in vivo studies are 
required to verify this. Finally, a ligand for Notch during valve morphogenesis is 
yet undetermined.  
3.  Disruption of Notch signaling impairs vascular smooth 
muscle cell recruitment during sprouting angiogenesis in  
the mouse retina (III, IV)
Blood vessel maturation occurs during angiogenesis and depends on mural 
recruitment. Contractile vascular smooth muscle cells are recruited to arteries, 
arterioles, veins and venules, where they provide structural support for these larger 
caliber vessels and regulate vessel diameter and blood flow by contracting (reviewed 
in (Armulik et al., 2011)). Endothelial Jag1/mural cell Notch3 signaling is required for 
postnatal VSMC maturation and maintenance of mural cell differentiation in mice 
(Benedito et al., 2009; High et al., 2008; Ruchoux et al., 2003). Notch3-/- mice still 
display αSMA+ mural cell coverage during early postnatal life, suggesting that initial 
recruitment of VSMCs occurs in these mice (Domenga et al., 2004). It should be 
noted that although the VSMCs detected in these mutant mice are αSMA+, they fail 
to express two other markers used to identify fully mature VSMCs, smoothelin and 
SM22, suggesting that VSMC maturation might also be compromised in Notch3-/- 
mice (Domenga et al., 2004). Considering that Notch1 is expressed in VSMCs and 
that Notch induces the expression of an important signaling protein in vascular 
mural cells, PDGFR-β, it was plausible to hypothesize that Notch1 regulates VSMC 
function during sprouting angiogenesis (Jin et al., 2008; Kitamoto et al., 2005; Liu 
et al., 2009). We asked whether Notch1 has overlapping or distinct functions from 
Notch3 in VSMCs. That is, we explored the hypothesis that Notch1 with Notch3 
may promote VSMC recruitment, differentiation or homeostasis.
To evaluate Notch1 function in VSMCs in the context of Notch3 deficiency, Notch1 
and Notch3 mutations were combined in mice. It should be noted that Notch1 is 
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expressed in both endothelial cells and VSMCs, whereas Notch3 is restricted to 
the vascular mural cells (Del Amo et al., 1992; Joutel et al., 2000; Kitamoto et al., 
2005; Sweeney et al., 2004). Notch3+/- mice were crossed to Notch1+/-;Notch3+/- 
mice and the retinal vasculature of all the resulting genotypes was analyzed (wild-
type, Notch3+/-, Notch3-/-, Notch1+/-, Notch1+/-;Notch3+/- and Notch1+/-;Notch3-/-). 
Notch3+/- mice were used as controls as they were phenotypically identical to their 
wild-type littermates. Compared to Notch3+/- controls, all other genotypes displayed 
increased number of tip cells and vascular density at P5 in the retinas, when the 
superficial plexus is actively undergoing robust angiogenic growth (Figure 1 in IV, 
generated by Kofler N). Hypersprouting observed in Notch1+/- mice was found, 
consistent with reduced endothelial Notch signaling which limits tip cell and sprout 
formation during retinal angiogenesis (Hellstrom et al., 2007; Suchting et al., 2007). 
Notch3-/- mice have been reported to display reduced vascular outgrowth from 
the optic nerve towards the retinal periphery (Liu et al., 2010b), which we also 
observed (Figure S2 in IV, generated by Kofler N). When total retinal endothelial 
content was normalized to vascularized area, retinal vascular density in Notch3-/- 
mice was increased despite reduced outgrowth. It is not clear why Notch3-/- retinas 
display reduced vascular growth towards retinal periphery as endothelial growth 
and sprouting still occurs as evident by increased number of tip cells and overall 
endothelial content. Thus, it is possible that reduced vascular growth towards the 
retinal periphery is due to defective directional guidance of growing endothelial 
sprouts and not reduced vascular plexus growth. As Notch3 is restricted to mural 
cells these data suggest that Notch3 signaling in mural cells regulates endothelial cell 
behavior and vascular patterning during sprouting angiogenesis. Reduced vascular 
outgrowth from the optic nerve towards the periphery was also observed in Notch1+/-
;Notch3+/- and Notch1+/-;Notch3-/- mice, providing further evidence for the role of 
Notch3 in regulating vascular growth in the retina. 
To evaluate Notch1 and Notch3 function in VSMCs, arterial αSMA+ VSMC 
coverage in control and mutant retinas was evaluated. In the mouse retina, αSMA+/
NG2-double positive VSMCs represent a more mature, contractile mural cell 
population, mainly observed around arterioles and to a lesser extent around venules 
(Hellstrom et al., 1999). Notch3-/- arterioles showed reduced αSMA+ VSMC coverage 
as previously reported (Liu et al., 2010b). Interestingly, Notch1+/- and Notch1+/-
;Notch3+/- retinas displayed a discontinuous αSMA staining pattern. However, the 
αSMA staining intensity was comparable to that observed in control retinas where 
VSMCs were observed. Notch1+/-;Notch3-/- arterioles displayed the most dramatic 
phenotype; the αSMA expressing mural cell coverage was significantly reduced 
when compared to Notch3-/- arterioles (Figure S3 in IV). 
We found that loss of one copy of Notch1 combined with loss of Notch3 resulted 
in a significantly more severe phenotype than Notch1 haploinsufficiency or Notch3 
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nullizygocity alone. Moreover, the significantly reduced αSMA+ VSMC coverage in 
Notch1+/-;Notch3-/- retinas correlated with a more severe vascular hypersprouting 
phenotype compared to Notch3-/- retinas. Importantly, loss of one Notch1 allele 
alone resulted in altered VSMC coverage suggesting a role for Notch1 in VSMC 
organization. Together these data suggest that both Notch1 and Notch3 are required 
for proper VSMC function during sprouting angiogenesis. It should, however, be 
noted that Notch1 is also expressed in the endothelium and therefore the severe 
hypersprouting phenotype seen in Notch1+/-;Notch3-/- retinas was likely due to a 
combination of endothelial and mural cell dysregulation. Although our data strongly 
suggest that Notch1 functions in VSMCs, it would be beneficial to analyze mice 
with a mural cell-specific deletion of Notch1 combined with loss of Notch3 in order 
to verify the mural cell-specific function. Furthermore, it should be determined 
how reduced Notch1 signaling affects VSMCs. Our data showed reduced αSMA+ 
VSMC coverage in the mutant retinas, however, it cannot be concluded whether 
this was due to reduced VSMC recruitment or reduced αSMA+ expression by the 
VSMCs that had been recruited. If it is the latter, then the significant reduction 
in Notch signaling in Notch1+/-;Notch3-/- retinas may have resulted in a failure in 
VSMC differentiation where the mural cells are more pericyte-like. As fully mature 
VSMCs express smoothelin and SM22 in addition to αSMA, it would be helpful 
to establish the expression pattern of these proteins in Notch1+/-;Notch3-/- retinas 
in order to determine if VSMC maturation is compromised in these mutant mice. 
Another approach to study the role of Notch in mural cells is through the use 
of biological inhibitors that target Notch function in vascular cells. We studied the 
role of Notch signaling in retinal angiogenesis and mural cell differentiation using 
such inhibitors. Kangsamaksin T. and Shawber C. designed and generated soluble 
Notch1 decoys that can be delivered in vivo via adenoviral infection and interfere with 
ligand/receptor interaction to inhibit Notch signaling. These Notch1 decoys consist 
of different regions of EGF-like repeats of NOTCH1 fused to human IgG Fc (Figure 
10). Notch/CSL reporter assay was utilized to determine the inhibitory capabilities 
of the decoys. Through these reporter assays, Notch1 decoys were identified that 
act as pan-ligand inhibitors or specifically inhibit either DLL/NOTCH or JAG/
NOTCH signaling. Decoys consisting of EGF-like repeats 1-24 (N11-24 decoy) or 1-36 
(N11-36 decoy) inhibited signaling through both DLL and JAG class ligands. Notch1 
decoy consisting of EGF-like repeats 1-13 (N11-13 decoy) preferentially inhibited DLL 
induced Notch1 signaling while decoy consisting of EGF-like repeats 10-24 (N110-24 
decoy) interfered with JAG/NOTCH signaling. 
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Results and discussion
Figure 10. Design of the Notch1 decoys. The Notch1 decoys consist of EGF-like repeats of  human NOTCH1 
fused to human IgG Fc. In all variants, EGF-like repeats are fused in frame with human IgG Fc. EGF-like repeats 
number 11 and 12 required for receptor/ligand interaction are marked with shading. LNR, LIN-12/NOTCH 
repeats; TM, transmembrane domain; RAM, CSL interaction domain; ANK, ankyrin repeats; NLS, nuclear 
location signal; PEST, proline-,glutamic acid-,serine-, threonine-rich sequence. Adapted from Kangsamaksin 
et al. 2015. NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by 
unique mechanisms to inhibit tumor growth. Cancer Discovery; 5(2); 182-97.
To ensure the decoys would be expressed and secreted by cells, 293T cells were 
transfected and total lysates and supernatants analyzed. All decoys were secreted 
into media by 293T cells. Of the two pan-ligand inhibitors, N11-24 was selected for 
further studies due to its better secretion into media. Co-immunoprecipitation 
studies further confirmed that N11-13 decoy physically interacts with DLL1 and DLL4 
but not JAG1 and JAG2, and N110-24 decoy with JAG1/2 but not DLL1/4. N11-24 decoy 
co-immunoprecipitated with both DLL and JAG class of ligands. None of the decoys 
interacted with the NOTCH1 itself. 
To determine how the Notch1 decoys affect angiogenesis they were evaluated 
using an in vitro angiogenesis assay that incorporates HUVEC-coated dextrin 
beads embedded in fibrin, where growth factors secreted by a fibroblast feeder 
layer induces sprouting of the HUVECs into the surrounding fibrin gel. HUVECs 
were infected with lentivirus encoding Fc (control), N110-24, N11-13 or N11-24 decoys and 
sprout formation evaluated on day 7. The HUVECs expressing Fc sprouted from the 
beads, branched and formed lumenized vessels day 7. Compared to the control, N11-
13 decoy expressing HUVECs displayed a hypersprouting phenotype characterized 
by increased growth and branch points. This result is in line with studies showing 
that inhibition of DLL4 induced Notch signaling results in an increased tip cell and 
sprout formation and subsequent vascular overgrowth. In contrast, N110-24 and N11-
Figure 10. Design of the Notch1 decoys. The Notch1 decoys consist of EGF-like repeats of human
NOTCH1 fused to human IgG Fc. In all variants, EGF-like repeats are fused in frame with human
IgG Fc. EGF-like repeats number 11 and 12 required for receptor/ligand interaction are marked with
shading. LNR, LIN-12/NOTCH repeats; TM, transmembrane domain; RAM, CSL interaction
domain; ANK, ankyrin repeats; NLS, nuclear location signal; PEST, proline-,glutamic acid-,serine-,
threonine-rich sequence. Adapted from Kangsamaksin et al. 2015. NOTCH decoys that selectively
block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor
growth. Cancer Discovery; 5(2); 182-97.
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24 decoys impaired sprouting of the HUVECs as evident by stunted sprouts and a 
reduced numbers of branch points observed. Thus, inhibition of JAG induced Notch 
signaling had an antiangiogenic effect. Interestingly, the antiangiogenic effect, - at 
least in this assay, was more potent than the proangiogenic effect caused by inhibition 
of DLL4/Notch signaling when using the pan-ligand inhibitor N11-24 decoy.
To determine how the Notch1 decoys affect angiogenesis in vivo, we assessed 
their activity using a postnatal murine retina as a model for vascular growth. 
Adenoviruses encoding different decoys or Fc control were delivered to P2 neonates 
via a subcutaneous injection, which led to hepatocyte infection by the adenoviruses 
and subsequent production and secretion of the Notch1 decoys into the bloodstream. 
All Notch1 decoys were detected in the bloodstream of the pups at the time of 
sacrifice. Compared to the Fc retinas, both retinas from N11-13 and N11-24 decoy 
expressing mice displayed a hypersprouting phenotype at P5, while N110-24 decoy 
retinas showed reduced vascular density (Figure 3D and E in III). We conclude 
that, during murine retinal angiogenesis, the pan-ligand N11-24 decoy functions more 
like a DLL4 inhibitor than a JAG1 inhibitor based upon the sprouting phenotype, 
which differs from the activity observed in the in vitro sprouting assay. The hyper-
sprouting phenotype seen in retinas of N11-13 decoy expressing mice is consistent 
with previous studies that have demonstrated the pro-sprouting effects of DLL4 
blockade (Hellstrom et al., 2007). Postnatal endothelial-specific loss of Jagged1 has 
been shown to cause reduced vascular density in the mouse retina and thus the 
antiangiogenic effect observed in the N110-24 decoy retinas is in line with previous 
findings (Benedito et al., 2009).
As JAG1 is known to regulate VSMC maturation and recruitment (High et al., 
2008), αSMA+ VSMC coverage was evaluated in the retinas isolated from Notch1 
decoy treated mouse neonates. Retinas from N11-13 decoy treated mice displayed 
comparable VSMC coverage and organization when compared to Fc control 
retinas. In contrast, N110-24 decoy treated mice displayed reduced αSMA
+ VSMCs 
along arterioles, consistent with previous work implicating Jag1/Notch in VSMC 
maturation. Interestingly, the pan-ligand inhibitor N11-24 decoy also caused reduced 
αSMA+ VSMCs, showing that while it causes hypersprouting by inhibiting Dll4/
Notch1 signaling in the endothelial cells of the newly formed sprouts, it also affects 
VSMC function likely via inhibition of Jagged1 mediated Notch signaling.
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Conclusions
Proper function of both blood and lymphatic vasculature is essential for normal 
development and health. For a long time, the lymphatic vasculature has been less 
studied than the blood vascular system. However, work by numerous investigators 
during the past decade has greatly increased our understanding of lymphatic 
development. In addition to definitely proving the venous origin of lymphatic 
system, several lymphatic regulators have been identified using transgenic mouse 
models. While new information has accumulated, it has become clear that the 
molecular mechanisms regulating lymphatic development and lymphangiogenesis 
are extremely complex.  
The Notch signaling pathway has been shown to mediate cell-fate decisions in 
various developmental settings as well as regulate cellular functions in numerous 
adult tissues. Notch has been extensively studied in the blood vascular system and 
shown to be required for normal vascular development. Recent work has identified 
Notch as a novel regulator of postnatal lymphatic growth where it can either promote 
or inhibit lymphangiogenesis, depending on the tissue and context. 
In the present study, we establish Notch as a novel regulator of embryonic 
lymphatic specification. Notch expression downregulates Prox1 in a subset of 
endothelial cells in the cardinal vein thus suppressing the lymphatic fate and 
maintaining venous fate in these cells. In contrast, Prox1 expression is induced in 
the cells lacking Notch activation which then go on to differentiate into lymphatic 
endothelial cells and migrate out of the cardinal vein. Although our results elucidate 
the molecular mechanism determining how a subset of venous endothelial cells 
adopt the lymphatic fate while others maintain their venous fate, it remains to be 
determined how Notch itself is regulated in the cardinal vein. Specifically, is Notch 
initially expressed throughout the cardinal vein and subsequently turned off in a 
subset of cells to allow lymphatic specification? If so, how is this achieved? It is 
possible that Notch signaling activity is restricted to certain cells through ligand 
availability, however, further studies are required to determine the exact mechanism.
Our data show that Notch no longer regulates Prox1 expression after E14.5, as 
has been reported before (Srinivasan et al., 2010). Therefore, it was not surprising to 
detect Notch1 expression in Prox1-expressing lymphatic endothelial cells during later 
embryonic development. Our studies demonstrate that Notch promotes lymphatic 
valve morphogenesis through regulation of valve-LEC clustering, reorientation and 
expression of known valve regulators, integrin-α9, fibronectin splice variant EIIIA 
and gap-junction protein connexin37. Like the initial lymphatic specification in 
the cardinal vein, lymphatic valve development also involves a specification event 
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during which a subset of LECs adopts a novel, valve-LEC fate. Considering the role 
of Notch in mediating binary cell-fate decision, it would be tempting to suggest that 
Notch mediates the separation of valve-LECs from the lymphatic duct wall LECs. 
However, our results do not demonstrate this. Instead, our data suggest that Notch 
promotes several steps of valve morphogenesis after the initiation phase, possibly by 
first guiding the clustering and reorientation of valve-LECs through upregulation of 
connexin37 in the valve-LECs and subsequently promoting valve leaflet formation 
by inducing integrin-α9 and fibronectin splice variant EIIIA. As Notch seems to 
regulate later steps of valve morphogenesis, further studies are required to determine 
the mechanism through which valve-LECs differentiate into a separate population. 
Future studies will hopefully also further elucidate how Notch interacts and/or 
cooperates with the other regulators to promote valve morphogenesis.
Finally, we show that Notch1 in addition to Notch3 is required for normal VSMC 
function during sprouting angiogenesis and that perturbed Notch signaling leads to 
abnormal vascular development in the postnatal mouse retina. Proper endothelial 
cell-mural cell interactions are crucial for vascular integrity and there are human 
conditions associated with impaired mural cell function. The human stroke syndrome 
CADASIL is an autosomal dominant disorder caused by mutations in NOTCH3 
and associated with progressive loss of cerebral VSMC coverage followed by loss 
of vascular integrity causing repeated strokes. As the condition is progressive, it is 
possible that another signaling mechanism is initially able to partially compensate 
for the abnormal function of Notch3. Considering that CADASIL is associated with 
progressive loss of VSMCs and that Notch3 null mice display normal mural cell 
coverage at birth, it is possible that Notch1 is sufficient for the initial recruitment and/
or maturation of VSMCs and that Notch3 is required for the maintenance of VSMC 
coverage later in life. Alternatively, only one copy functional copy of NOTCH3 may 
be necessary for early VSMC events. The Notch1 decoys presented in publication III 
inhibit ligand interaction with all Notch proteins and therefore we cannot separate 
the effects of impaired Notch1 and Notch3 activation on VSMCs in our decoy studies. 
However, as the Notch1 decoys are ligand-specific, they will undoubtedly provide 
a useful tool for studying effects of ligand-specific inhibition in vitro and in vivo.
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